Module 9
Management of Coinfections in HIV-Positive Injecting Drug Users

Treatment and Care for HIV-Positive Injecting Drug Users
Module 9

Management of coinfections in HIV-positive injecting drug users

Participant Manual

2007
The Association of Southeast Asian Nations (ASEAN) was established on 8 August 1967. The Member States of the Association are Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand and Viet Nam. The ASEAN Secretariat is based in Jakarta, Indonesia.

For inquiries, contact The Public Affairs Office, The ASEAN Secretariat, 70A Jalan Sisingamangaraja, Jakarta 12110, Indonesia, Phone: (62 21) 724-3372, 726-2991, Fax: (62 21) 739-8234, 724-3504. E-mail: public@aseansec.org. General information on ASEAN appears on-line at the ASEAN Website: www.aseansec.org.

Catalogue-in-Publication Data
Treatment and Care for HIV-Positive Injecting Drug Users
Jakarta: ASEAN Secretariat, December 2007

616.9792
1. ASEAN – USAID
2. HIV – Drugs – Modules


This publication is available on the internet at www.aseansec.org, www.fhi.org and www.searo.who.int/hiv-aids publications.

Copies may be requested from:
The ASEAN Secretariat, 70A, Jl. Sisingamangaraja, Jakarta 12110, Indonesia. e-mail: public@aseansec.org
and
Family Health International, Asia/Pacific Regional Office, 19th Floor, Tower 3, Sindhorn Building, 130–132 Wireless Road, Lumpini, Phatumwan, Bangkok 10330, Thailand, e-mail: sunee@fhibkk.org
and
HIV Unit, Department of Communicable Diseases, World Health Organization, Regional Office for South-East Asia, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi-110 002, India, e-mail: hiv@searo.who.int

Module 1: Drug use and HIV in Asia: participant manual
Module 2: Comprehensive services for injecting drug users – participant manual
Module 3: Initial patient assessment – participant manual
Module 4: Managing opioid dependence – participant manual
Module 5: Managing non-opioid drug dependence – participant manual
Module 6: Managing ART in injecting drug users – participant manual
Module 7: Adherence counselling for injecting drug users – participant manual
Module 8: Drug interactions – participant manual
Module 10: Managing pain in HIV-infected injecting drug users – participant manual
Module 11: Psychiatric illness, psychosocial care and sexual health – participant manual
Module 12: Continuing medical education – participant manual
Trainer manual: Treatment and care for HIV-positive injecting drug users

© ASEAN Secretariat 2007

All rights reserved. The text of this publication may be freely quoted or reprinted with proper acknowledgment.

Typesetting and Design: Macro Graphics Pvt. Ltd.
Printed in India
Sub-module 9.1: HIV/HCV and HIV/HBV coinfections

Overview

Hepatitis C coinfection

Natural history

Effect of HCV on HIV progression

Effect of HIV on HCV progression

Treatment of HCV in HIV coinfection

Treatment of HIV in HCV coinfection

Conclusion

Hepatitis B coinfection

Natural history

Effect of HBV on HIV progression

Effect of HIV on HBV progression

Treatment of HBV in HIV coinfection

Treatment of HIV in HBV coinfection

Conclusion

References and recommended reading

Sub-module 9.2: Management of HIV/TB coinfection in IDUs

Overview

Care and support for HIV-infected individuals with active TB

Co-trimoxazole preventive treatment and HIV-associated active TB

Principles of antiretroviral therapy (ART)

References and recommended reading

Exercise 9.2.1: Case studies

Annex 1: PowerPoint presentation 9.1: HIV/HCV and HIV/HBV coinfections

Annex 2: PowerPoint presentation 9.2: Management of HIV/TB coinfection in IDUs
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>3TC</td>
<td>lamivudine</td>
</tr>
<tr>
<td>ABC</td>
<td>abacavir</td>
</tr>
<tr>
<td>AFB</td>
<td>acid-fast bacilli</td>
</tr>
<tr>
<td>AIDS</td>
<td>acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase (liver enzyme)</td>
</tr>
<tr>
<td>ART</td>
<td>antiretroviral therapy</td>
</tr>
<tr>
<td>ARV</td>
<td>antiretroviral</td>
</tr>
<tr>
<td>ASEAN</td>
<td>Association of Southeast Asian Nations</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase (liver enzyme)</td>
</tr>
<tr>
<td>AZT</td>
<td>zidovudine (also ZDV)</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CCC</td>
<td>comprehensive continuum of care</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention (US Government)</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CPT</td>
<td>co-trimoxazole preventive treatment</td>
</tr>
<tr>
<td>CTX</td>
<td>co-trimoxazole</td>
</tr>
<tr>
<td>d4T</td>
<td>stavudine</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DOTS</td>
<td>directly observed treatment, short course</td>
</tr>
<tr>
<td>EFV</td>
<td>efavirenz</td>
</tr>
<tr>
<td>ESLD</td>
<td>end-stage liver disease</td>
</tr>
<tr>
<td>ETR</td>
<td>end-of-treatment response</td>
</tr>
<tr>
<td>EVR</td>
<td>early virological response</td>
</tr>
<tr>
<td>FHI</td>
<td>Family Health International</td>
</tr>
<tr>
<td>FTC</td>
<td>emtricitabine</td>
</tr>
<tr>
<td>GFATM</td>
<td>Global Fund to Fight AIDS, Tuberculosis and Malaria</td>
</tr>
<tr>
<td>HBcAb</td>
<td>hepatitis B core antibody</td>
</tr>
<tr>
<td>HBeAb</td>
<td>hepatitis B e antibody</td>
</tr>
<tr>
<td>HBeAg</td>
<td>hepatitis B e antigen</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B surface antigen</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular cancer</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>HEENT</td>
<td>head eye ear nose and throat</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>IDUs</td>
<td>injecting drug users</td>
</tr>
<tr>
<td>IFN</td>
<td>interferon</td>
</tr>
<tr>
<td>IRIS</td>
<td>immune reconstitution inflammatory syndrome</td>
</tr>
<tr>
<td>LFT</td>
<td>liver function tests</td>
</tr>
<tr>
<td>MAC</td>
<td><em>Mycobacterium avium</em> complex</td>
</tr>
<tr>
<td>NGO</td>
<td>nongovernmental organization</td>
</tr>
<tr>
<td>NNRTI</td>
<td>non-nucleoside reverse transcriptase inhibitors</td>
</tr>
<tr>
<td>NR</td>
<td>non-responder</td>
</tr>
<tr>
<td>NRTI</td>
<td>nucleoside reverse transcriptase inhibitors</td>
</tr>
<tr>
<td>NSAID</td>
<td>non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>NVP</td>
<td>nevirapine</td>
</tr>
<tr>
<td>OI</td>
<td>opportunistic infection</td>
</tr>
<tr>
<td>OST</td>
<td>opioid substitution therapy</td>
</tr>
<tr>
<td>PCP</td>
<td><em>Pneumocystis jiroveci</em> pneumonia</td>
</tr>
<tr>
<td>PEG-IFN</td>
<td>pegylated interferon</td>
</tr>
<tr>
<td>PI</td>
<td>protease inhibitor</td>
</tr>
<tr>
<td>PLWHA</td>
<td>people living with HIV and AIDS</td>
</tr>
<tr>
<td>RBV</td>
<td>ribavirin</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized control trial</td>
</tr>
<tr>
<td>RHZE</td>
<td>TB drug treatment regimen involving 4 drugs (H=isoniazid, R=rifampicin, E=ethambutol, Z=pyrazinamide)</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>SS</td>
<td>sputum smear</td>
</tr>
<tr>
<td>SSRI</td>
<td>selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td>SVR</td>
<td>sustained virological response</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TDF</td>
<td>tenofovir</td>
</tr>
<tr>
<td>TNP-plus</td>
<td>Thai Network for People Living with HIV/AIDS</td>
</tr>
<tr>
<td>TST</td>
<td>tuberculin skin test</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>USAID</td>
<td>United States Agency for International Development</td>
</tr>
<tr>
<td>VCT</td>
<td>voluntary counselling and testing</td>
</tr>
<tr>
<td>VL</td>
<td>viral load</td>
</tr>
<tr>
<td>WCC</td>
<td>while cell count</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>ZDV</td>
<td>zidovudine (also AZT)</td>
</tr>
</tbody>
</table>
OVERVIEW

Objectives:

By the end of the session the participants will:

- Understand the epidemiology of viral hepatitis/HIV coinfection
- Understand the influence of viral hepatitis on progression of HIV
- Understand the influence of HIV on progression of viral hepatitis
- Understand the approach to HCV and HBV treatment in the context of HIV infection
- Understand the approach to HIV treatment in the context of viral hepatitis, including how to choose an appropriate ART regimen and monitor liver function
- Understand the importance of preventing bloodborne virus transmission in coinfection
- Understand the limitations of hepatitis management in resource-limited settings

Time to complete session:

1 hour 45 minutes

Session content:

Consider both HCV/HIV and HBV/HIV coinfection:

- Epidemiology
- Natural history
- Effect of HCV on HIV progression
- Effect of HIV on HCV progression
- Treatment of HCV in HIV coinfection
- Treatment of HIV in HCV coinfection
- Summary

Training materials:

- PowerPoint presentation 9.1: HIV/HCV and HIV/HBV coinfections in HIV-infected IDUs
- Sub-module 9.1: HIV/HCV and HIV/HBV coinfections
HEPATITIS C COINFECTION

Epidemiology

There are 170 million individuals living with hepatitis C in the world. Most are from developing countries. There are a number of reasons for this which include unsterile medical injections, transfusions, cultural practices where blood is potentially exchanged between individuals, and injecting drug use. The prevalence by country is shown in Figure 1:

Figure 1. Prevalence of hepatitis C across the world, 2005

Source: Shepard CW, Finelli L, Alter MJ. Lancet Infectious Diseases, 2005

<table>
<thead>
<tr>
<th>WHO Region</th>
<th>Total population (millions)</th>
<th>HCV prevalence (%)</th>
<th>Infected population (millions)</th>
<th>Number of countries by WHO Region where data are not available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>602</td>
<td>5.3</td>
<td>31.9</td>
<td>12</td>
</tr>
<tr>
<td>Americas</td>
<td>785</td>
<td>1.7</td>
<td>13.1</td>
<td>7</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>466</td>
<td>4.6</td>
<td>21.3</td>
<td>7</td>
</tr>
<tr>
<td>Europe</td>
<td>858</td>
<td>1.03</td>
<td>8.98</td>
<td>19</td>
</tr>
<tr>
<td>South-East Asia</td>
<td>1500</td>
<td>2.15</td>
<td>32.3</td>
<td>3</td>
</tr>
<tr>
<td>Western Pacific</td>
<td>1600</td>
<td>3.9</td>
<td>62.2</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td>5811</td>
<td>3.1</td>
<td>169.7</td>
<td>59</td>
</tr>
</tbody>
</table>

Source: Shepard CW, Finelli L, Alter MJ. Lancet Infectious Diseases, 2005

Although injecting drug use is a very common way of acquiring HCV, the proportion of HCV cases attributable to injecting drug use is lower in developing than developed countries. Screening of blood and blood products for HCV is an effective way to reduce transmission. This was first introduced in the late 1980s in Australia, Europe and the USA, but is now common in many countries. The country with the highest population prevalence of HCV is Egypt, a consequence of unsterile injections during a schistosomiasis treatment programme in the second half of the last century.
Within IDU populations, sharing of contaminated injecting equipment such as needles and syringes is the most common mode of HCV acquisition. Sharing of other equipment such as spoons and filters has also been associated with the transmission of HCV, though this is less common. HCV appears easier to transmit than HIV, and therefore the prevalence of HCV in an injecting drug user (IDU) population is often much higher than the HIV prevalence. HCV is difficult to transmit by unprotected sexual intercourse, though recent studies suggest that traumatic sexual practices are associated with HCV transmission.

The epidemiology of HCV/HIV coinfection is less well understood. Generally speaking, this co-infection, by the nature of the shared transmission routes, is transmitted by injecting drug use; however, transmission can also be sexual. Thus, coinfection is more common in IDUs than in the general population. HCV is more difficult to clear spontaneously in the presence of HIV; therefore, HIV-positive IDUs are much more likely to have HCV than their HIV-negative counterparts. In a number of countries in Asia, the prevalence of HIV/HCV coinfection among HIV-positive IDUs is >95% (parts of China, Thailand, Viet Nam). By contrast, most HIV-positive individuals are not HCV-positive in those countries when injecting drug use is not a major transmission route for HIV (see Figure 2; note Italy and Spain have a greater proportion of HIV infection attributable to injecting drug use).

Figure 2. Prevalence of HCV coinfection in HIV-positive individuals by country: CAESAR study


The virus

Hepatitis C was formerly known as non-A non-B hepatitis. It was named hepatitis C in 1989 when the virus was discovered. It is a member of the Flaviviridae family. Other viruses of this family include Japanese encephalitis, dengue and West Nile virus. It is unrelated to the other hepatitis viruses, except that they all cause inflammation of the liver. It is an RNA virus, and is therefore highly variable in its expression (many mutations during replication similar to HIV). This is one reason why it is able to evade the immune system. During infection, HCV exists as many similar, but not identical, species (quasispecies) generally within the same genotype. There are nine genotypes (numbers 1–9), within which there are subtypes (letters a, b, c), so a viral infection is known as, for
example, 1a or 3a or 2b, etc.). Genotypes 1, 2, and 3 are widely distributed throughout the West and in East Asia (Japan, China, Taiwan, Thailand). Types 5 and 6 are mainly confined to South Africa and South-East Asia, respectively, in contrast to type 4, which is predominant in the Middle East and Central Africa.

HCV is transmitted primarily by blood-to-blood contact. Sharing injecting equipment and blood transfusion are the most efficient mechanisms of transmission. The rate of vertical transmission (mother to child) is low (<5%). The most important factor in vertical transmission is the level of virus in the mother (high level relates to a high chance of transmission). Sexual transmission is remote in mono-infection due to HCV. In HCV/HIV coinfection, sexual transmission is more common, though still very low. Hepatitis C viral load can be substantially higher in the presence of co-morbid HIV infection. Factors increasing the sexual transmission of hepatitis C in coinfection are high hepatitis C viral load, trauma during sex and possibly the presence of a sexually transmitted infection (STI).

**NATURAL HISTORY**

The natural history of HCV infection is relatively benign, at least in the first few years of infection. Once transmitted, a viraemia develops. This is followed by seroconversion (development of antibodies to hepatitis C), which takes between six weeks and six months to occur. Acute infection is asymptomatic in 60% of individuals. Common symptoms include fatigue, lethargy, nausea and other constitutional symptoms. Jaundice is uncommon and occurs in <25% of individuals.

Acute infection spontaneously clears in about 15% of individuals. This generally occurs within the first three to six months of treatment. There is no relationship between the genotype of HCV infection and the likelihood of clearance. The presence of HIV or other immunosuppression markedly reduces the likelihood of viral clearance. The rate of clearance among HIV-positive individuals is between 5% and 8%. If the virus is not cleared within the first few months of treatment, it is very unlikely that viral clearance will occur. Individuals with HIV coinfection generally have substantially higher viral loads than HCV mono-infected individuals.

Chronic HCV infection has an indolent course. Around one third of individuals with chronic hepatitis C infection have mild hepatitis with normal liver function tests (LFT). The other two thirds have abnormal LFT with moderate to severe inflammation. The rate of cirrhosis (significant liver scarring resulting in impaired liver function) is around 20% in those with chronic hepatitis after 20 years of infection.

**Figure 3. Typical serological course of hepatitis C**

Typical serological course of hepatitis C.
The effect of HCV on HIV progression is somewhat controversial. A number of studies have demonstrated that HCV may accelerate the course of HIV infection. The mechanism is not well known, although HCV is known to have immunomodulatory effects. A number of studies have also demonstrated that when controlled for influencing variables such as CD4 count, age and whether or not on antiretroviral therapy (ART), there is no difference in the progression of HIV between HCV/HIV coinfected and HIV mono-infected individuals. The latter variable (ART) is probably the most important factor. Coinfection is much more common in IDUs, who often have reduced access to effective HIV treatment, thus differences in disease outcome may be attributable to differences in HIV treatment access.

**EFFECT OF HCV ON HIV PROGRESSION**

HIV does influence the progression of HCV in coinfection. Infection with HIV has been shown to result in a higher hepatitis C viral load, liver fibrosis, progression to cirrhosis, liver failure and hepatocellular carcinoma (HCC). Factors associated with an increased risk of liver disease progression in people with HIV/HCV coinfection include heavy alcohol (ethanol) intake (>50 g/day), older age at HCV acquisition, low CD4 count, increased quasispecies variability and occult hepatitis B virus (HBV) infection.

**EFFECT OF HIV ON HCV PROGRESSION**

Figure 4. The course of HCV infection
Despite this, adequate immune reconstitution with ART has been shown to modify the course of HCV in HIV infection including slowing the rate of progression of liver fibrosis and reducing complications from HCV. Better survival rates among individuals with HIV treated with effective ART have also increased the proportion of liver-related mortality and morbidity in developed countries.

Hepatitis C information: do and avoid

**DO**
- Vaccinate against hepatitis B and A if required
- Go for regular health check-ups
- Stop or reduce alcohol intake: alcohol use significantly increases the risk of developing cirrhosis and liver cancer
- Protect from reinfection: the presence of hepatitis C antibodies will not protect one from getting infected again
- Eat a balanced diet of fresh vegetables, fruits, beans, whole grains and lean meats; a healthy balance of protein in the diet
- Drink lots of fluids
- Exercise regularly
- Follow a stress reduction plan

**AVOID**
- Drinking alcohol; even one drink a day can accelerate the progression of liver disease
- Taking large amounts of acetaminophen (paracetamol) as it is toxic to the liver
- Taking acetaminophen and alcohol as together they can cause severe liver damage
- Breathing in pollutants, chemicals, cleaning products, fumes from paint, paint thinners, chemical solvents, spray adhesives, insect sprays and cleaners as these can be harmful to the liver
- Foods with high salt, sugar or fat content
- Too much fried foods
- High doses of vitamins A, D, E or K
- Taking iron supplements unless advised by the doctor

**TREATMENT OF HCV IN HIV COINFECTION**

Hepatitis C treatment is expensive and this limits access to treatment in Asia.

_Treatment regimen_

Standard treatment is a subcutaneous injection of pegylated interferon (PEG–IFN) weekly in combination with ribavirin (RBV) tablets or capsules (dose depending on weight and genotype) twice daily. The duration of treatment for HIV/HCV coinfection is 48 weeks for all genotypes. In HCV mono-infection, the treatment length can vary, depending on the genotype.

There are two companies that manufacture PEG-IFN, and the dosage will vary depending on the brand used. Pegasys (Roche) is PEG-IFN α2a and is a standard dose for all weights; Pegintron (Schering Plough) is PEG-IFN α2b and the dose varies depending on the weight of the individual. Standard IFN was used in the past, but needs to be administered three times a week and is much less effective.
Effectiveness (sustained virological response)

It is necessary to understand the HCV treatment terminology of HCV infection.

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early virological response (EVR)</td>
<td>Usually a reduction in viral load 12 weeks into treatment, though this varies by level of reduction and timing</td>
</tr>
<tr>
<td>End-of-treatment response (ETR)</td>
<td>Undetectable HCV RNA at the end of treatment</td>
</tr>
<tr>
<td>Sustained virological response (SVR)</td>
<td>Undetectable HCV RNA at 24 weeks after completion of treatment. Obtaining a sustained virological response is often referred to as a “cure”</td>
</tr>
<tr>
<td>Non-responder (NR)</td>
<td>No significant reduction in HCV RNA levels (&lt;2 log^−) after a specified interval of treatment (usually 24 weeks), or no significant decrease in HCV RNA, but HCV RNA never becomes undetectable during treatment. Some non-responders may have improved liver histology after treatment</td>
</tr>
</tbody>
</table>

Combination PEG-IFN and RBV treatment is effective, with sustained virological response (SVR) rates of between 27% and 40% overall, and up to 73% in genotypes 2 and 3. The treatment of acute hepatitis C in the context of HIV coinfection may be more effective, with an SVR of just over 70% regardless of genotype.

A number of studies have shown that it is possible to treat active IDUs for HCV mono-infection and achieve good outcomes. However, few studies have looked at HCV treatment in HIV-coinfected active IDUs.

HCV treatment is more effective with better immune function and treatment is most effective with adequate immune function. It is recommended that ART be commenced in individuals with a CD4 count of less than 200 cells/mm^3 prior to initiation of treatment for HCV. As a consequence, appropriate ART regimens and effective ART for IDUs in Asia will facilitate effective HCV treatment when this becomes more widely available.

If the CD4 count is <200 cells/mm^3 then treat HIV first; once a CD4 count >350 cells/mm^3 is reached treat HCV. If the CD4 count is >200 cells/mm^3, then it is reasonable to treat hepatitis C first.

Reinfection and relapse

There are limited data on reinfection and relapse in HIV/HCV coinfected though it appears that reinfection rates are low. Necessary precautions are advised if injecting continues during and after completion of hepatitis C treatment (e.g. the use of clean needles and syringes, and sterile injection techniques).

Reinfection refers to infection with a new HCV. The reinfection rate in coinfection is unknown. In HCV mono-infection it is less than 5%. Relapse refers to a re-emergence of the same virus strain, usually relating to viral suppression during treatment beyond the detectable limit and increasing replication post-treatment, bringing the viral load back into the detectable range. The likelihood of relapse is reduced with combination treatment (PEG-IFN and RBV) compared with monotherapy.
Management of coinfections in HIV-positive injecting drug users

(PEG-IFN only). With combination treatment, the relapse rate is around 10% in genotype 1 and 2% in genotypes 2 and 3. This means that between treatment completion and six months after treatment completion, about 10% of genotype 1 HCV moves from being undetectable to becoming detectable, while only 2% of genotypes 2 and 3 do. Information on other genotypes is not available.

Feasibility

Interferon-based hepatitis C treatment regimens are difficult to tolerate. Side-effects are many and varied, and patients may need significant psychosocial and medical support. Depression is a very common side-effect and many IDUs may require antidepressant medication by the end of treatment. Selective serotonin reuptake inhibitors (SSRIs) are the first line of therapy in the management of depression during IFN treatment. There is currently no consensus on the use of prophylactic SSRI.

Combination PEG-IFN and RBV therapy:

Contraindications: Severe cardiac disease (<6 months prior); haemoglobinopathies (e.g. thalassaemia, sickle cell anaemia); creatinine clearance <50 ml/min; decompensated liver cirrhosis; recent, current immunosuppressive therapy (except short-term steroid); autoimmune disease; immunosuppressed transplant patients; uncontrolled thyroid disease; pregnancy, male partners of pregnant women (use contraception for longer than or for 6 months after treatment conclusion), lactation

Precautions: Cardiac, renal disease (monitor); ensure adequate hydration; severe hepatic dysfunction; initial, ongoing laboratory test monitoring (see full product information); diabetes, hypertension (monitor visual function); severe psychiatric conditions (including history); psoriasis; sarcoidosis; the elderly; children <18 years

Adverse reactions: Possibly teratogenic; bone marrow suppression; haemolysis; fever; ocular, pulmonary, cardiovascular effects; local reactions; fatigue; flu-like symptoms; infection; headache; rigors; gastrointestinal upset; anorexia; arthralgia, myalgia; psychiatric, CNS disturbance; insomnia; alopecia; pruritus; dry skin; dental, periodontal disorders; kidney, liver graft rejection (possible); hypertriglyceridaemia; thyroid dysfunction; autoantibody development; autoimmune disorders including thrombocytopenic purpura; gout; others, see full product information

Drug interactions: Nucleoside analogues including didanosine (ddl), stavudine (d4T), zidovudine (AZT); CYP1A2, CYP2C8/9, CYP2D6 metabolized drugs; shosaikoto (Chinese herb)

Particular attention should be paid to patients with cirrhosis. There is a higher risk of liver decompensation during anti-HCV treatment in those with cirrhosis. These individuals should be managed in collaboration with a gastroenterologist or hepatologist.

Alcohol use should be discouraged during treatment. This impairs the effectiveness of treatment, particularly when drinking is above 10 g ethanol equivalent per day (1 small beer).

Substance use should ideally be treated and stabilized prior to initiation of treatment, with continued management during treatment. Opiate dependence is ideally managed with opioid substitution therapy (OST). Clean injecting equipment should be accessible in case of relapse or continued heroin or other injecting drug use.

Participant Manual
TREATMENT OF HIV IN HCV COINFECTION

It has become clear that effective HIV treatment (ART) reduces the progression of liver disease in HIV/HCV coinfected individuals. Despite this, there are a number of precautions that need to be taken.

Hepatotoxicity

Abnormal liver function tests are common in HIV/HCV coinfected individuals on ART. Severe dysfunction can lead to hepatotoxicity (markedly abnormal liver function, alanine aminotransferase [ALT] >5x upper limit of normal [ULN]). The mechanism is unclear but may be a combination of the direct effect of medication on the liver cells or a hypersensitivity reaction. Additionally, restoration of immune function with ART may induce immune reactions against the liver cells, causing liver damage – this is known as IRIS (see Sub-module 6.5).

NNTRI-based regimens

The WHO 2006 guidelines recommend that efavirenz (EFN) is the preferred non-nucleoside reverse transcriptase inhibitor (NNRTI) option wherever possible in patients who have HIV and hepatitis C coinfection. It is recommended that nevirapine (NVP) be used with care and regular monitoring done in patients who have known HIV/HCV coinfection and grade 3 or lower elevation of ALT. NVP is not recommended for those with ALT elevations of grade 4 or higher.

NTRIs

Nucleoside reverse transcriptase inhibitors (NTRIs) have been associated with hepatic steatosis leading to some hepatic dysfunction. Only limited data are available, and generally NTRIs are well tolerated during HIV treatment in coinfection.

PI-based regimens

Protease inhibitors (PIs) affect the liver either directly or by affecting the metabolism of other drugs to hepatotoxic ranges. Ritonavir (RTV), particularly at higher doses, has been associated with increased liver function abnormalities and hepatotoxicity. The risk of hepatotoxicity is more than doubled in HIV/HCV coinfection compared with HIV monoinfection.

Choice of ART regimen

The decision as to what ART regimen should be used in the treatment of HIV/HCV coinfection depends on the individual. NVP should possibly be avoided in moderate to severe liver dysfunction. Liver function should be monitored at treatment initiation and throughout treatment.

Monitoring during initiation and treatment

IDUs with HIV should be tested for HCV antibody prior to HIV treatment initiation. A positive test in the presence of abnormal liver function tests (particularly ALT) should indicate HCV infection. Individuals should be vaccinated against HBV if necessary and if the CD4 count >200 cells/mm³, and asked to avoid alcohol. The LFT should be monitored.
CONCLUSION

- HIV/HCV coinfection is very common in HIV-positive IDUs.
- Test for HCV-Ab + LFT prior to initiating ART.
- Treat HIV first if CD4 count <200 cells/mm³; then HCV if drugs are available.
- Avoid alcohol, treat substance use.
- Advise use of sterile injecting equipment.
- Use EFV instead of NVP for those with HIV/HCV coinfection.
- It is possible to use NVP in individuals with <grade 3 elevation of ALT if LFT can be monitored regularly.
- Do not use NVP if there is grade 4 elevation of ALT.

HEPATITIS B COINFECTION

Epidemiology

There are over 400 million people living with chronic hepatitis B worldwide, although it is estimated that one third of the world’s population has – at some stage – had HBV infection. The vast majority are in developing countries, including Asia where infection is endemic among neonates and infants. Indeed, hepatitis B is endemic in all of Africa, some parts of South America, Alaska, northern Canada and parts of Greenland, eastern Europe, the eastern Mediterranean area, South-East Asia, China and the Pacific Islands, except Australia, New Zealand and Japan. In most of these areas, 5–15% of the population are chronically infected carriers of HBV. HBV is also more common in IDUs in both developing and developed countries. In western Europe, North America and Australia the prevalence of HBV infection is less than 0.5%.

Figure 5. Geographical distribution of chronic HBV infection

Hepatitis B is transmitted vertically (mother to child) in about 5% of pregnancies among hepatitis B
carriers, and horizontally through unprotected sex, sharing of injecting equipment and importantly through close contact particularly between infants and neonates (perinatal transmission). It is also transmitted through unsterile medical injections and unscreened blood products.

It is important to know how HBV is not transmitted. HBV is NOT transmitted through food or water, casual contact, such as hugging or shaking hands, or through kissing, sneezing or coughing. It is not transmitted through breastfeeding. Vaccination does not help individuals who are already infected with HBV.

Chronic infection with HBV occurs in 90% of individuals infected in the first six months of life, while if acute infection occurs in adults, >95% clear the virus completely.

The global epidemiology of HBV/HIV coinfection is less well understood. Due to the common pathways of transmission and endemic HBV infection in Asia, the prevalence of past exposure in IDUs is extremely high.

Figure 6. Prevalence of chronic HBV virus and HCV infection in HIV-positive populations by HIV risk group

The virus and testing

Hepatitis B is a DNA virus of the Hepadnavirus family. It infects and replicates within the hepatocytes (liver cells) though it causes little or no damage to the cells. Liver damage is caused by the immune response to the virus and hence chronic infection results in greater hepatic dysfunction from a chronic immune response.

There are seven hepatitis B genotypes. A is pandemic, B and C are found in Asia, D in southern Europe, E in Africa, F in the USA, and G in the USA and France. There appears to be little difference in the extent of disease caused by the different genotypes, although genotype C has been associated with more severe and prolonged disease and may be more difficult to treat. There are a number of different components of the virus that have been identified, which are useful in assessing an individual’s state of infection.
Management of coinfections in HIV-positive injecting drug users

Participant Manual

All IDUs should be tested for hepatitis B, especially if treatment for HIV is to begin. Testing in HIV-positive individuals is more difficult, as markers of the disease may not always be present. Initial tests should include HBsAg and if possible HBsAb and HBcAb. In HIV-positive individuals, HBsAg may be negative although the virus is present and therefore, if available, HBV DNA should be done for confirmation of the disease (occult HBV infection).

### Natural History

In infancy and early childhood (<2 years old) acute infection is usually asymptomatic but much more likely to result in chronic infection (>90% of individuals <6 months). In adulthood, acute infection is usually symptomatic with jaundice, nausea, fatigue and lethargy in 75% of people, but only <5% go on to have chronic infection. The presence of HIV is more likely to result in chronic infection.

In the presence of HIV, HBV viral replication and therefore its viral load are higher. Liver injury is usually reduced with immunosuppression such as in HIV infection. In some people with very high viral loads, HBV can directly cause injury to the liver cells (known as fibrosing cholestatic hepatitis).

---

**Table 1. Markers of hepatitis B disease**

<table>
<thead>
<tr>
<th>Marker</th>
<th>Full form</th>
<th>Indicates</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg</td>
<td>Hepatitis B surface antigen</td>
<td>Current infection with hepatitis B (a carrier)</td>
</tr>
<tr>
<td>HBsAb</td>
<td>Hepatitis B surface antibody</td>
<td>Immunoprotection against hepatitis from either vaccination or previous exposure</td>
</tr>
<tr>
<td>HBcAb</td>
<td>Hepatitis B core antibody</td>
<td>Previous exposure to hepatitis B</td>
</tr>
<tr>
<td>HBeAg</td>
<td>Hepatitis B e antigen</td>
<td>Marker of active replication/active disease</td>
</tr>
<tr>
<td>HBeAb</td>
<td>Hepatitis B e antibody</td>
<td>Marker of inactive disease, so called &quot;e seroconversion&quot;</td>
</tr>
<tr>
<td>HBV DNA</td>
<td>Hepatitis B DNA</td>
<td>Presence indicates active replication and disease. Amount of DNA is &quot;HBV viral load&quot;</td>
</tr>
</tbody>
</table>


**Table 2. Interpretation of hepatitis B tests**

<table>
<thead>
<tr>
<th>Test combination</th>
<th>Results</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg</td>
<td>–</td>
<td>Susceptible to hepatitis B</td>
</tr>
<tr>
<td>HBcAb</td>
<td>–</td>
<td>Past history of HBV with current immunoprotection</td>
</tr>
<tr>
<td>HBsAb</td>
<td>–</td>
<td>Immune due to hepatitis B vaccination</td>
</tr>
<tr>
<td>HBsAg</td>
<td>–</td>
<td>Past history of HBV infection</td>
</tr>
<tr>
<td>HBcAb</td>
<td>+</td>
<td>Past history of HBV infection</td>
</tr>
<tr>
<td>HBsAb</td>
<td>–</td>
<td>Past history of HBV infection</td>
</tr>
</tbody>
</table>

Figure 7. Natural history of hepatitis B
EFFECT OF HBV ON HIV PROGRESSION

Early studies in the pre-ART era suggested that HBV infection could be a cofactor in HIV disease; however, more recently it has become clear that this is not the case when other factors are taken into consideration. Evidence from the ART era has suggested that HBV does not appear to alter the course of HIV.

EFFECT OF HIV ON HBV PROGRESSION

HIV coinfection influences the course and natural history of HBV infection by impairing the quantity and quality of the innate and adaptive immune response. The rates of spontaneous resolution after acute infection and spontaneous anti-HBe and anti-HBs seroconversion are decreased, and levels of HBV replication are increased in HIV-infected patients. A more rapid progression of liver fibrosis and a higher rate of cirrhosis leading to decompensation (but not HCC) have been demonstrated in coinfected patients. The risk of HBV-associated end-stage liver disease (ESLD) and liver-related mortality may be increased by HIV coinfection.

ART can have a major impact on HBV coinfection because of the restoration of immune responses and improved regulation of the immune system. In addition, at least three ARVs (3TC, TDF and FTC) are potent inhibitors of HBV replication. There is also some evidence that 3TC may prevent acute hepatitis B infection in HIV-positive individuals exposed to hepatitis on an ART regimen that contains 3TC.

TREATMENT OF HBV IN HIV COINFECTION

Prevention

There is an effective vaccine available for the prevention of hepatitis B. All at-risk individuals who are not immunoprotected (no HBsAb nor HbcAb) should be vaccinated. Those who are HIV-positive are less likely to respond to HBV vaccine (especially if the CD4 count is <200 cells/mm³), have lower mean antibody titres (by a factor of about 30), and lose protective antibody levels more quickly.

The vaccination regimen in coinfection should be 0, 1, 6 months or 0, 1, 2, 12 months. Non-responders should have a further three shots at double the dose.

Treatment regimen

Treatment of hepatitis B in HIV coinfection is complex. HIV coinfected individuals are less likely to respond to treatment, yet a number of agents used to treat hepatitis B are also used to treat HIV.

There are a number of drugs registered to treat hepatitis B: 3TC (a nucleoside analogue), adefovir, dipivoxil (nucleotide analogue reverse transcriptase inhibitor), entecavir (a purine-derived nucleoside analogue) and PEG-IFN α2a; TDF (a nucleotide reverse transcriptase inhibitor) and FTC are also effective in suppressing HBV.

3TC inhibits HBV replication in up to 87% of HIV/HBV coinfected patients, while anti-HBe seroconversion occurs in up to 11% of patients. Mutations in the replication mechanism of HBV lead to resistance to 3TC in 47% of patients at two years and 90% at four years of treatment.

Adefovir dipivoxil taken 10 mg PO daily has been shown to reduce the viral load though resistance does develop. In combination with 3TC, resistance is less likely.
TDF has been shown to be effective in treating hepatitis B in coinfected individuals and there is no evidence of resistance developing. It is also effective against 3TC resistant hepatitis B.

Entecavir has been shown to reduce the hepatitis B viral load in coinfected individuals with a low risk of development of resistance by HBV and by HIV to ART. Its suggested use is in people not requiring ART.

PEG-IFN (48 weeks of weekly 180 log subcutaneous injection) has been shown to be more effective than 3TC in inducing HBeAg seroconversion, reducing the viral load and in normalizing liver function.

**Side-effects:** 3TC is well tolerated and safe; however, development of HBV resistance is frequent. Adefovir has a nephrotoxic potential and may at least theoretically induce ARV resistance in HBV/HIV patients treated with it. TDF has gastrointestinal side-effects, is associated with hypophosphataemia that has not been known to induce serious osteopenia so far, and may have a nephrotoxic potential.

The following treatment is recommended (Australasian Society for HIV Medicine 2003):

**In individuals requiring HBV treatment but not HIV treatment:**

It is reasonable to delay treatment for hepatitis B. If treatment is desired then use PEG-IFN or a non-ART agent to avoid the development of resistance to the agent (e.g. entecavir or adefovir dipivoxil).

**In individuals requiring both HBV treatment and HIV treatment:**

ARVs with HBV activity should be included in the regimen. If a single agent is used, TDF has a better resistance profile. If two agents can be used then 3TC and TDF should be used. 3TC can be used alone but HBV resistance will eventually occur.

**In individuals not requiring HBV treatment, but requiring HIV treatment:**

If hepatitis B replication is under control (HBV DNA <4 log^{10} copies/ml), ART need not contain agents with dual activity. The type of ART regimen should be determined as per usual indications.

**In individuals with resistance to 3TC:**

Suspect if the HBV viral load increases by 1 log^{10} copies/ml. Add TDF to the regimen if only 3TC is being used. Switching to adefovir or entecavir can also be dose.

**In individuals with cirrhosis:**

These patients are at risk for hepatic decompensation (failure) when ART is initiated, particularly if the CD4 count is low and viral load of HBV is high. Therefore, use a combination (e.g. 3TC + TDF) initially to reduce the viral load before commencing full ART.

Treatment of HBV is expensive, and therefore inaccessible to many people. In resource-poor settings, the key issues are:

- Vaccination for hepatitis B
- Stabilization of drug use with appropriate treatment (e.g. OST)
- Reduction and ideally cessation of alcohol use
- Use of ARVs in the treatment of HIV with activity against HBV.
Effectiveness

Limited data are available on the effectiveness of HBV treatment in HBV/HIV coinfection. Effectiveness of HBV treatment can be measured by:

- **HBV DNA level:**
  - This is called the HBV viral load and is the best way to monitor the effectiveness of treatment. It is also the most expensive.
  - 3TC reduces the viral load by almost $3 \log_{10}$ copies/ml after 1 year of treatment.
  - Adefovir dipiroxil reduces viral load by $4 \log_{10}$ copies/ml after 1 year of treatment.
  - TDF reduces the viral load by $4 \log_{10}$ copies/ml regardless of resistance to 3TC.

- **HBeAg seroconversion:**
  - This signifies the development of HBeAb as a result of treatment and indicates control of replication.
  - Only a minority of individuals on treatment will have HBeAg seroconversion.

- **ALT levels:**
  - ALT levels are an inexpensive way to monitor therapy, but can be difficult to interpret.
  - There is a clear correlation between the decrease in viral load and reduction in ALT levels.
  - There is also a clear correlation between improvement in ALT levels and that of liver histology scores during therapy.
  - ALT can rise during:
    - Control of viral replication (due to restoration of immune function)
    - Liver toxicity from drug therapy.

Resistance

Resistance is more common with 3TC therapy and less so with adefovir dipivoxil or TDF. Mutations that explain resistance have been identified, but resistance testing is expensive and often unavailable.

It is important to remember that TDF is active against 3TC-resistant HBV.

TREATMENT OF HIV IN HBV COINFECTION

This is discussed above, but the important aspects are:

- It is usually unnecessary to treat HBV infection when there is no indication for HIV treatment. Additionally exposing the individual to the development of resistance to ARVs is unwise.
- When HIV treatment is indicated, use a regimen with agents such as 3TC and/or TDF, which also have activity against HBV.
- In individuals with cirrhosis, low CD4 counts and high HBV viral load, control HBV replication prior to starting ART.
- EFV is the preferred NNRTI option in individuals with HBV/HIV coinfection.
- NVP may be used with care and regular monitoring in patients who have known HBV/HIV coinfection and $\leq$grade 3 elevation of ALT.
- NVP is not recommended for those with $\geq$grade 4 ALT elevation.
HBV flares on ART
HBV flares may occur during ART in HBV/HIV coinfection as a presentation of the immune reconstitution inflammatory syndrome (IRIS). Flares are characterized by an acute rise in hepatic transaminases accompanied by symptoms of acute hepatitis (fatigue, abdominal pain and jaundice). These reactions generally occur during the first few months of treatment and may be difficult to distinguish from ART-induced hepatic toxicity. Drugs active against HBV should preferably be continued during a suspected flare, and, if the patient is receiving 3TC monotherapy, consideration should be given to the addition of TDF if available. If it is not possible to distinguish a serious hepatitis B flare from a grade 4 ART toxicity, all ARV drugs should be withheld until the clinical condition improves.

HBV flares when ART is stopped
There is also a risk of a flare of HBV when HBV-active drugs are stopped. Fatal cases of acute HBV infection have been documented in HBV/HIV coinfected patients who discontinue 3TC monotherapy. Patients with coinfection who need to stop the HBV-active drugs in the HIV treatment regimen (3TC, FTC or TDF) should be closely monitored. If a patient is known to have chronic HBV, it is recommended that 3TC be continued as part of second-line ART following initial ART failure, even if it has been used in first-line treatment.

CONCLUSION
- Hepatitis B is very common in HIV-positive IDUs.
- All HIV-positive IDUs should be screened for HBV.
- All HIV-positive IDUs should be vaccinated against HBV if not already immunoprotected.
- Treatment for hepatitis B should generally be withheld until there is an indication to treat HIV.
- HIV treatment regimens in the context of hepatitis B should incorporate agents that have activity against hepatitis B.
- ALT should be monitored during HBV treatment.
- TDF should be used in case of 3TC resistance.
- EFV is the preferred NNRTI option in individuals with HBV/HIV coinfection.
- NVP may be used with care and regular monitoring in patients who have known HBV/HIV coinfection and ≤grade 3 elevation of ALT.
- NVP is not recommended for those with ≥grade 4 ALT elevation.

REFERENCES AND RECOMMENDED READING
Epidemiology and prevention of viral hepatitis A to E: hepatitis B virus. Division of viral hepatitis, CDC slide set found at: http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/index.htm


*HIVandhepatitis.com* web site (http://www.hivandhepatitis.com/).


OVERVIEW

Objectives:

By the end of the session participants will be able:

- To describe the epidemiology of TB among IDUs and PLWHA
- To use the WHO guidelines to prescribe co-trimoxazole prophylaxis in HIV-infected patients
- To describe care and treatment interventions for HIV-infected IDUs with active TB
- To appropriately use ART in HIV-infected IDUs with active TB

Time to complete session:

1 hour 15 minutes

Session content:

- Care and support for HIV-infected individuals with active TB
- Co-trimoxazole preventive treatment and HIV-associated active TB
- Principles of antiretroviral therapy

Training materials:

- PowerPoint presentation 9.2: Management of HIV/TB coinfection in IDUs
- Sub-module 9.2: Management of HIV/TB coinfection in IDUs
- Exercise 9.2.1: Case studies 1, 2, 3
CARE AND SUPPORT FOR HIV-INFECTED INDIVIDUALS WITH ACTIVE TB

Background

The public health approach to decrease the burden of TB/HIV requires more effective delivery of the available interventions for HIV-infected individuals including those with TB/HIV coinfection or active TB disease by health service providers. Increased population coverage by these interventions is also needed. HIV-infected patients, including those with active TB, should benefit from HIV/AIDS care, treatment and support.

Whereas previous national TB and AIDS programmes have largely pursued separate courses, they need to look for synergy in supporting health service providers to deliver care and treatment for HIV-infected individuals with TB. A key operational issue is that HIV programmes are largely vertical, with care centred in a small number of tertiary referral centres or specialized clinics in most countries. TB programmes are administratively vertical, but services are disseminated and integrated into the primary health-care systems down to the sub-district/health centre level. Other issues remain in determining optimal cross-referral procedures, care integration and patient monitoring. Significant administrative, social, stigma-related and ethical barriers to successful collaboration remain to be addressed. Thailand is the only country in the Region, and one of the few in the world, where TB and HIV services are equally decentralized down to the sub-district level.

Concept of comprehensive HIV/AIDS care

Comprehensive HIV/AIDS care is a holistic approach to meeting the needs of HIV-infected individuals. Several studies have been conducted in the Asia-Pacific Region to assess the needs of persons living with HIV (PLWHA). The following needs were identified (WHO SEARO, 2002a).

Providing comprehensive HIV care includes:

- Clinical and nursing care for those affected to alleviate the symptoms of HIV disease
- Psychosocial support and ongoing counselling
- Financial support or employment opportunities for PLWHA
- Housing and legal assistance
- Care and support for orphans and widows
- Information and training of caregivers and affected people.

Comprehensive care should link the formal (health facilities including health centres) and informal (family and community care) sections of the health system in a cohesive network of services. The success of a comprehensive continuum of care model depends on the cooperation and collaboration of health-care workers at all levels (primary, secondary and tertiary) and the active involvement of communities at risk, PLWHA and their families and caregivers. The “continuum of care” stands for the seamless movement of PLWHA to and from the formal to the informal health services.

If comprehensive care across the continuum operates successfully, then it will facilitate:

- An improvement in the duration and quality of life of PLWHA
- A reduction in the level of stigma and discrimination in clinical and community care settings
- Alleviation of the impact of HIV and AIDS
The comprehensive care model builds on the existing health system. Strategies to provide comprehensive care include:

- Involving formal and informal health-care services at the district and sub-district levels in the national scale-up plan
- Defining the roles of each institution and health cadre at all levels of care including monitoring and supervision
- Defining and/or establishing referral networks so that PLWHA can access appropriate services when they are needed
- Establishing formal linkages between community-based and facility-based services to regularly exchange information and strengthen partnerships between care providers
- Capacity building including at the district and sub-district levels and developing appropriate training tools and methodologies
- Providing appropriate opportunities for health-care workers and care providers (both formal and informal) to identify gaps in skills and services.

The full involvement of PLWHA peers in HIV services such as in day-care centres or centres for comprehensive and continuous care is a key approach for ensuring treatment adherence and facilitating follow up of people.

Experience from Thailand

The consortium of Thai Network for People Living with HIV/AIDS (TNP-plus) and other NGOs received support from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) in 2003 to strengthen PLWHA involvement in the comprehensive continuum of care (CCC) centres. As of October 2004 the programme had been expanded to 114 hospitals and one women's prison covering nearly 10 000 PLWHA on care and treatment. The number of PLWHA followed in each CCC centre ranged from 6 to 350. PLWHA support groups provide education on ART literacy and peer counselling including for treatment adherence. They also work as volunteers for providing logistic support to health-care workers and patients such as filling in forms, transporting files, problem-solving, conducting inpatient visits, providing outreach for home care and support, and tracing of defaulters. PLWHA disclose their HIV status upon entering the PLWHA group. At the district level this implies disclosure of the HIV status to the family and community. These groups allow PLWHA to address factors that may affect their adherence to ART, such as side-effects, lack of family and emotional support, lack of treatment information and advice on taking pills regularly and on time. PLWHA groups and NGOs also support and encourage enrolment in the national ART programme (Kumphitak et al. 2004).

Models for the delivery of HIV/AIDS care and treatment for HIV-infected TB patients, in particular during TB treatment, are less well described. Collaboration between the TB and HIV programmes is essential for the delivery of an integrated package of HIV and TB services for HIV-infected TB patients (WHO, 2004).

**CO-TRIMOXAZOLE PREVENTIVE TREATMENT AND HIV-ASSOCIATED ACTIVE TB**

Co-trimoxazole (CTX) preventive treatment is the gold standard in developed countries for HIV-infected individuals with CD4+ T-cell counts <200 cells/mm³ to prevent *Pneumocystis jiroveci* pneumonia (PCP), a common opportunistic infection (OI) with a high mortality (USPHA/IDSA, 2001). This common OI and other bacterial infections cause considerable morbidity during the treatment of HIV-infected TB cases. Studies have shown that preventive treatment with CTX against
these infections decreased morbidity and mortality in HIV-infected patients with TB disease in Africa. A study conducted in Côte d’Ivoire (Africa) showed a significant benefit of CTX prophylaxis against some bacterial causes of pneumonia and diarrhoea and their complications (Wiktor, 1999; Wagner, 2001; Havlir, 1999). A cohort study conducted in Malawi compared an HIV-seropositive TB cohort receiving CTX for 12 months with a historical comparison group who were not receiving CTX. Both cohorts received TB treatment as per the national directly observed treatment, short-course (DOTS) strategy. Survival of HIV-positive TB patients improved dramatically with the addition of CTX prophylaxis to the treatment regimen (Mwaungulu, 2004).

Data on the prevalence of OIs and the use of CTX are less well documented in Asian countries. PCP is the second most commonly reported OI in Thailand and India after TB (MOPH Thailand, 2003; Hira, 1998). The Thai HIV/AIDS clinical management guidelines recommend the use of CTX (MOPH, 2000). All HIV-infected patients with a CD4+ T-cell count <200 cells/mm³ are offered CTX in Thai health facilities. Further studies are necessary to evaluate the best models for the use of CTX in HIV-infected TB patients in Asia and the Pacific.

While all HIV-exposed infants and children should benefit from CTX preventive therapy, this intervention is particularly important in children coinfected with TB and HIV.


**PRINCIPLES OF ANTIRETROVIRAL THERAPY (ART)**

**Antiretroviral treatment and TB**

Due to the high prevalence of TB among HIV-infected individuals living in the Asia–Pacific Region, many patients who are candidates for ART will have active TB (Narain, 2002). HIV-infected persons with active TB will often be offered ART because those with pulmonary TB meet the criteria for WHO stage 3 disease and those with extrapulmonary TB for WHO stage 4. ART may be highly beneficial in reducing case-fatality rates in these persons (Girardi, 2001; Badri, 2002). In addition, patients already receiving ART may develop clinical TB.

ART in individuals undergoing treatment for TB merits special consideration because co-management of HIV and TB is complicated by:

- Drug interactions between rifampicin and several classes of ARVs
- High pill burden
- Difficulties in adherence to treatment
- Drug toxicity
- Immune reconstitution inflammatory syndrome (IRIS) (Kwara, 2005)

The treatment of TB remains a central priority for patient care. TB treatment following the DOTS strategy should be initiated promptly in diagnosed cases of TB regardless of the HIV serostatus (Santoro-Lopes, 2002).

Other guidelines and materials should be consulted for more guidance on ART. In this rapidly evolving field, it is highly recommended to consult regularly updated treatment guidelines and the literature. The WHO websites are useful sources of up-to-date guidance (http://www.who.int/HIV, http://www.searo.who.int/aids, http://www.wpro.who.int). They also provide links to treatment-related websites.
Antiretroviral drugs in adults and adolescents

**When to start ART in adults and adolescents**

WHO recommends that in resource-limited settings, HIV-infected adolescents and adults should start ART when they have confirmed HIV infection and one of the conditions shown in Tables 3 and 4.

**When to start ART in adults and adolescents with active TB disease**

In HIV-infected persons being treated for TB, the optimal timing of initiation of ART is not known. On the one hand, case-fatality rates in patients with TB during the first two months of TB treatment are high, particularly in high HIV-prevalence settings, arguing for early treatment initiation (Corbett, 2003). On the other hand, considerations of drug interactions between rifampicin and several classes of ARVs, a high pill burden, toxicity and IRIS support the later initiation of ART.

<table>
<thead>
<tr>
<th>Table 3. Recommendations for starting antiretroviral therapy in adults and adolescents with documented HIV infection if CD4 testing is available</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinically advanced and severe/very advanced HIV disease</strong></td>
</tr>
<tr>
<td>WHO stage 4</td>
</tr>
<tr>
<td>WHO stage 3</td>
</tr>
<tr>
<td><strong>Mildly symptomatic and asymptomatic disease</strong></td>
</tr>
<tr>
<td>WHO stage 2, 1</td>
</tr>
<tr>
<td>$^a$ CD4 cell count advisable to assist with determining need for immediate therapy. For example, pulmonary TB may occur at any CD4 level and other conditions may be mimicked by non-HIV aetiologies (e.g. chronic diarrhoea, prolonged fever).</td>
</tr>
<tr>
<td>$^b$ The precise CD4 count above 200 cells/mm$^3$ at which ART should be started has not been established.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 4. Recommendations for starting antiretroviral therapy in adults and adolescents with documented HIV infection if CD4 testing is not available</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinically advanced and severe/very advanced HIV disease</strong></td>
</tr>
<tr>
<td>WHO stage 4</td>
</tr>
<tr>
<td>WHO stage 3</td>
</tr>
<tr>
<td><strong>Mildly symptomatic and asymptomatic disease</strong></td>
</tr>
<tr>
<td>WHO stage 2</td>
</tr>
<tr>
<td>$^a$ A TLC of ≤1200 cells/mm$^3$ can be substituted for the CD4+ T-cell count when the latter is unavailable and there is moderate HIV disease (stage 2). It is not useful in asymptomatic patients. Thus, in the absence of CD4 testing, asymptomatic HIV-infected patients (WHO stage 1) should not be treated because there is currently no other reliable marker available in severely resource-constrained settings.</td>
</tr>
</tbody>
</table>
Management of coinfections in HIV-positive injecting drug users

The optimum time at which to commence ART in a patient with TB/HIV coinfection is unknown. Initiation of ART is recommended for TB patients at very high risk for HIV disease progression and mortality. For patients with a CD4+ T-cell count <200 cells/mm³, ART is recommended as soon as the TB therapy is tolerated, usually between 2 weeks and 2 months (Table 5). For patients who develop TB with CD4+ T-cell counts in the 200–350 cells/mm³ range, ART should be started after the first two months of TB therapy, because the toxicity of TB treatment is greatest in the first two months of treatment. In patients with CD4+ T-cell counts >350 cells/mm³, ART should be deferred and the patient monitored closely.

Where CD4 counts are not available, WHO recommends that ART be considered after the intensive phase of TB treatment. Clinical judgement may indicate earlier or later initiation.

Table 5. ART recommendations for individuals with HIV-related TB if CD4 count is available

<table>
<thead>
<tr>
<th>CD4+ T-cell count</th>
<th>Recommended regimen</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;200 cells/mm³</td>
<td>Start TB treatment. Start one of the regimens below as soon as TB treatment is tolerated (between 2 weeks and 2 months)b. EFV-containing regimen b</td>
<td>Recommend ART</td>
</tr>
<tr>
<td>200–350 cells/mm³</td>
<td>Start TB treatment. Start one of the regimens below after initiation phase (if severely compromised start earlier).</td>
<td>Recommend ART</td>
</tr>
<tr>
<td>&gt;350 cells/mm³</td>
<td>Start TB treatment. Start one of the regimens below after initiation phase (if severely compromised start earlier).</td>
<td>Defer ARTc</td>
</tr>
<tr>
<td>Not available</td>
<td>Start TB treatment. Start one of the regimens below after initiation phase (if severely compromised start earlier).</td>
<td>Consider ARTc,d</td>
</tr>
</tbody>
</table>

- a Timing of ART initiation should be up to clinical judgement based on other signs of immunodeficiency.
- b First-line treatment regimen alternatives to EFV- or ABC (300 mg bid)-containing regimens. For other alternatives please see text below.
- c Unless non-TB WHO stage 4 conditions are present. Otherwise, consider ART upon completion of TB treatment.
- d If no other signs of immunodeficiency are present and patient is improving on TB treatment, ART should be started upon completion of TB treatment.

First-line ART regimens in the setting of TB treatment for adults and adolescents

An NNRTI plus two NRTIs is the recommended first-line ART regimen in resource-limited settings. Accumulating data from these settings support the use of first-line NNRTI-containing ARV regimens in patients receiving rifampicin for TB.

EFV is the recommended NNRTI, but its use may be impaired by its limited availability in several nationally supported ART programmes and restrictions in pregnant women or women of childbearing age (Bristol-Myers Squibb Company, 2005). NVP is an alternative agent, but has a greater risk of hepatotoxicity, which can be life-threatening. This makes the drug less suitable for treating patients who use other hepatotoxic medications, such as rifampicin and for persons with high CD4+ T-cell count or for whom the CD4+ T-cell count is not known. Triple NRTIs (ABC + zidovudine [AZT] + 3TC or TDF + AZT + 3TC) are an additional option and can be used during pregnancy, in HIV-2 infection or in patients with higher CD4+ T-cell counts; data are limited to support this recommendation (Department of Health & Human Services, 2006).
Development of active TB in adults and adolescents receiving ART

ART decreases the incidence of TB in treated cohorts by approximately 80%, but rates of TB among treated patients nevertheless remain persistently higher than among HIV-negative individuals (Williams, 2003). Although recent evidence shows that TB should be considered as an advanced/late HIV OI, the development of an episode of TB still occurs across a wide range of CD4+ T-cell counts (Scano, 2005). In addition, subclinical or undiagnosed TB often presents within the first six months after initiation of ART (Seyler, 2005). For these reasons, it is difficult to determine if an episode of TB in a patient receiving ART indicates treatment failure and requires switching of the ART regimen.

Until further data are available, WHO recommends that if an episode of TB occurs in a patient receiving ART, an ART regimen compatible with the TB treatment regimen should be continued during TB treatment. If a person is receiving a NVP-based regimen, EFV should be substituted for NVP and continued until two weeks after rifampicin is completed, then EFV should be substituted for NVP. If EFV is contraindicated or not available, the NVP-based regimen should be continued during TB treatment with careful monitoring of liver function and drug toxicity.
ART second-line treatment options are limited for patients with TB with clear evidence of a failing ART regimen. The second-line treatment options are described elsewhere.

**Immune reconstitution inflammatory syndrome**

IRIS, a worsening of clinical disease after initial improvement, may occur in up to a third of persons with TB who initiate ART (see Sub-module 6.5).

The average time of onset is two months after ART initiation, but can occur as early as five days. TB-associated IRIS most commonly presents with fever and clinical deterioration of pre-existing lymphadenopathy or respiratory disease. Several reports suggest that IRIS is more common if ART is started early in the course of TB treatment and if the patient has a low CD4+ T-cell count. Most cases resolve without any intervention and ART can be safely continued. Serious reactions such as tracheal compression due to massive adenopathy may require a short course of steroids (1–2 mg/kg of prednisolone) based on clinical judgement (Narita, 1998; Kumarasamy, 2004; Lawn, 2005).

**REFERENCES AND RECOMMENDED READING**


Van Cutsem G et al. TB/HIV co-infected patients on rifampicin containing treatment have equivalent ART treatment outcomes, and concurrent use of nevirapine is not associated with increased hepatotoxicity. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, 24–27 July 2005, Rio de Janeiro, Brazil.


EXERCISE 9.2.1

CASE STUDIES

Case 1

A 36-year-old male presents with a four-week history of fever, cough, fatigue, poor appetite and a weight loss of 6 kg. He just tested positive for HIV in the voluntary counselling and testing (VCT) centre today and was referred to the clinic for further evaluation. He does not have any previous illnesses and is not on any medications.

He first injected drugs in 1999 and quit in 2003. He currently works as a motorcycle taxi driver and lives with his wife.

Physical exam:
- Temp 39°C, HR 110 beats/min, BP 110/90 mmHg, RR 18/min, weight 44 kg
- Head eye ear nose and throat (HEENT): oral thrush
- Neck: multiple lymph nodes on the right side 1–2 cm in size
- Lungs: scattered rales, no wheezing
- Heart, abdomen: normal
- Skin: no rashes

1) What WHO clinical stage is the patient in?

2) What further evaluation would you do at this time?

3) What is the most probable diagnosis?

4) What further diagnostic evaluation would you do?

5) What is the diagnosis?

6) What do you treat first: TB or HIV?

7) Does the patient meet the criteria for initiating ART?

8) When will you start ART?

9) What ART regimen would you start?
Case 2

A 24-year-old male is referred from the TB clinic after testing positive for HIV. He is on the third week of treatment for pulmonary TB and is tolerating the treatment well. His fever has resolved and he gained 2 kg since starting treatment. His cough is better but he still coughs at night.

His medical history is notable for chronic hepatitis B infection and one episode of herpes zoster two years ago. He smokes ½ pack of cigarettes a day. He does not drink alcohol. He still uses heroin twice a day, but has been trying to decrease the amount he uses each time.

Physical exam:
No significant abnormalities noted

Laboratory exam:
- CBC: WBC 5600 cells/mm³ (25% lymphocytes), Hb 10 g/dl, platelets 155 000/µl
- CD4 225 cells/mm³
- ALT 76 IU/ml, AST 65 IU/ml
- HCV positive, HBsAg positive

1) Does the patient meet the criteria for initiating ART?

2) Does current injecting drug use disqualify the patient for ART?

3) When would you start ART in this patient?

4) Which ART regimen would you use?
Case 3

A 20-year-old male patient returns to the clinic for routine follow up. He was started on ART with d4T/3TC/NVP six weeks ago. Baseline CD4 count was 105 cells/mm³. At four weeks he was feeling well without any symptoms and results of routine blood testing (complete blood count [CBC], ALT, AST) were normal. Today he complains of fever, cough with white sputum, and a 1 kg weight loss over the past 10 days.

He started injecting drugs when he was 14 years of age and was admitted to a rehabilitation centre four years ago. He was released from the centre six months ago and now lives with his family. He does not use drugs currently.

Physical exam:

- Temp 38.0°C, RR 16/min, HR 88 beats/min, BP 120/76 mmHg
- HEENT: no thrush
- Neck: no lymphadenopathy
- Lungs: rales and wheezing on the upper left side
- Heart: regular rhythm without murmurs
- Abdomen: normal
- Skin: no rashes
- Chest X-ray: left upper lobe infiltrate
- Sputum AFB: positive

1) What is the diagnosis?

2) Do these findings indicate failure of the ART regimen?

3) The patient is started on rifampicin, isoniazid, pyrazinamide and ethambutol (RHZE) for TB. Will you stop the ART?

4) Will you change the ART regimen?
CASE STUDIES: ANSWERS AND NOTES

Case 1

1) What WHO clinical stage is the patient in?
   Clinical stage 3: weight loss >10% and oral thrush

2) What further evaluation would you do at this time?
   Routine laboratory tests, chest X-ray, sputum for acid-fast bacilli (AFB), CD4 count (if available)
   Results of laboratory testing:
   - CBC: WBC 3600 (25% lymphocytes)
   - Haematocrit 31%, Hb 9.2 g/dl, platelets 135 000/µl
   - CD4: 95 cells/mm³
   - ALT 46 IU/ml, AST 50 IU/ml
   - HCV positive, HBsAg negative
   - AFB x 3: negative
   - Chest X-ray: Right upper lobe infiltrates and interstitial infiltrate throughout

3) What is the most probable diagnosis?
   Although the sputum is AFB negative, the most likely diagnosis is TB. The interstitial infiltrate on CXR is commonly seen with miliary TB, in which tubercle bacilli spread through the blood and the sputum is usually negative for AFB. The differential diagnosis would also include PCP and bacterial pneumonia. Less common causes would be viral pneumonia, fungal pneumonia, and Mycobacterium avium complex (MAC).

4) What further diagnostic evaluation would you do?
   Rule out TB first: a repeat AFB would be reasonable. If AFB not found in the sputum, do a lymph node aspirate or biopsy. Sputum staining for bacteria, PCP and fungi should be done, if available. Cultures may also be helpful, although the results take longer.
   Result: Aspiration of a cervical lymph node is positive for AFB.

5) What is the diagnosis?
   TB lymphadenitis. TB is presumably causing the pulmonary disease as well.

6) What is the WHO clinical stage of the patient?
   Extrapulmonary TB indicates WHO clinical stage 4.

7) What do you treat first: the TB or the HIV?
   Start TB treatment first and consider ART when indicated.
8) **Does the patient fulfil the criteria for ART?**
   Yes, WHO stage 4 and CD4 count 95 cells/mm³.

9) **When will you start ART?**
   Between 2 and 8 weeks, as soon as the patient tolerates the TB treatment.

10) **What ART would you start?**
    Preferred regimen: 2 NRTI + EFV
    Other options: 2 NRTI + NVP, 3 NRTI

**Case 2**

1) **Does the patient meet the criteria for initiating ART?**
   Yes, clinical stage 3 (pulmonary TB) and CD4 count <350 cells/mm³

2) **Does current injecting drug use disqualify the patient for ART?**
   No, active drug use is not a reason to deny care or ART.
   However, the patient should be referred for counselling and drug treatment, where available.
   Drug use can be associated with decreased adherence: active IDUs should be carefully counselled and monitored for adherence.

3) **When would you start ART in this patient?**
   After 8 weeks, when the intensive phase of TB treatment is completed.

4) **What ART regimen would you use?**
   If the patient continues on rifampicin:
   - EFV-based regimens preferred
   - NVP or triple NRTI regimens can be given, but monitor closely for hepatic toxicity if NVP used
   If the patient continues on isoniazid and ethambutol:
   - EFV or NVP regimens can be given
   NOTE: The patient has high risk for hepatic toxicity due to chronic HBV, baseline elevated ALT, and use of TB drugs. Check ALT at 8 weeks before starting ART and follow closely.
Case 3

1) What is the diagnosis?
   Active pulmonary TB.

2) Is this failure of the ART regimen?
   No, development of active pulmonary TB while on ART does not indicate treatment failure and is common in the first six months of treatment.

3) The patient is started on RHZE for TB. Will you stop the ART?
   NO! DO NOT STOP THE ART! You should continue ART while treating TB.

4) Will you change the ART regimen?
   Concerns about NVP use with rifampin.
   Preferred regimen is 2 NRTI + EFV, if available.
   Other options: 3 NRTI or continue 2 NRTI + NVP.
   If NVP continued: monitor closely for hepatic toxicity.
Presentation 9.1: HIV/HCV and HIV/HBV coinfections

Session objectives

- Understand the epidemiology and background of HCV/HIV and HBV/HIV coinfection
- The influence of viral hepatitis on HIV progression
- The influence of HIV on progression of viral hepatitis
- Coinfection
- Treatment of HIV in viral hepatitis coinfection
- Treatment of viral hepatitis in HIV coinfection
- Future treatment of viral hepatitis in the presence of HIV infection

Viral hepatitis coinfection in HIV-infected IDUs

Hepatitis C coinfection

Management of hepatitis C in HIV-coinfected IDUs

Epidemiology of HCV

- 170 million people have hepatitis C worldwide
- Between 5% and 60% of HIV-positive individuals worldwide are HCV antibody positive (depending on the country)
- Over 90% of HIV-infected IDUs are also HCV-positive
- Transmitted by:
  - Blood-to-blood contact
  - Blood products (unscreened) such as transfusions
  - Not commonly spread via sexual contact except (potentially) in setting of HIV/HCV coinfection in men who have sex with men (MSM) especially with sexually transmitted infections (STIs)
  - Rarely mother-to-child except in setting of HIV/HCV coinfection [19% HIV/HCV versus 3.5% HCV]

Background: HCV virus

- RNA flavivirus similar to dengue and Japanese encephalitis virus
- RNA viruses (such as HIV) are more prone to mutate than DNA viruses (such as HBV) and therefore often harder to treat
- Exists as many different variants during infection (quasispecies)
- 9 genotypes (subtypes), distribution varies
  - Genotypes 1, 2, 3 → Western countries and East Asia
  - Genotype 4 → Middle East and Central Africa
  - Genotypes 5, 6 → South Africa and South-East Asia

Epidemiology

Prevalence of HCV worldwide


Annex 1

Background: HCV virus

- RNA flavivirus similar to dengue and Japanese encephalitis virus
- RNA viruses (such as HIV) are more prone to mutate than DNA viruses (such as HBV) and therefore often harder to treat
- Exists as many different variants during infection (quasispecies)
- 9 genotypes (subtypes), distribution varies
  - Genotypes 1, 2, 3 → Western countries and East Asia
  - Genotype 4 → Middle East and Central Africa
  - Genotypes 5, 6 → South Africa and South-East Asia

Epidemiology of HCV

- 170 million people have hepatitis C worldwide
- Between 5% and 60% of HIV-positive individuals worldwide are HCV antibody positive (depending on the country)
- Over 90% of HIV-infected IDUs are also HCV-positive
- Transmitted by:
  - Blood-to-blood contact
  - Blood products (unscreened) such as transfusions
  - Not commonly spread via sexual contact except (potentially) in setting of HIV/HCV coinfection in men who have sex with men (MSM) especially with sexually transmitted infections (STIs)
  - Rarely mother-to-child except in setting of HIV/HCV coinfection [19% HIV/HCV versus 3.5% HCV]
Management of coinfections in HIV-positive injecting drug users

Impact of HCV on HIV disease progression

- Limited long-term effect on HIV-associated mortality when CD4 count, age and HIV treatment taken into account
- HCV/HIV coinfected individuals may do worse than others many as more likely to be IDUs
- Increased LFT abnormalities following initiation of ARV (possibly immune, viral, toxicity)
- Liver-associated mortality increased in HIV/HCV coinfecion
- Infection with multiple HCV genotypes may increase progression of HIV disease

Impact of ART on liver disease mortality (EuroSIDA)

- Heavy alcohol (ethanol) intake (>50 g/day) [some studies]
- Uncontrolled plasma HIV RNA
- Low CD4 count [some studies]
- Increased quasispecies variability
- Occult HBV infection (hepatitis B infection that is undetectable)
- Effective ART improves outcome of HCV disease [especially if suppresses plasma HIV RNA]

Effect of HCV on HIV progression

- Increased progression to cirrhosis [at 10 years HIV-uninfected 2.6% versus 14.9% HIV-infected]
- Increased liver failure, hepatocellular carcinoma (HCC) increased risk 6x to 11x in HIV coinfected
- Factors associated with progression of liver disease in HCV/HIV coinfecion are:
  - Heavy alcohol (ethanol) intake (>50 g/day) [some studies]
  - Uncontrolled plasma HIV RNA
  - Low CD4 count [some studies]
  - Increased quasispecies variability
  - Occult HBV infection (hepatitis B infection that is undetectable)
  - Effective ART improves outcome of HCV disease [especially if suppresses plasma HIV RNA]
**Mr NS – 1**
- Mr NS, age 24 years, married man, presents after wife found to HIV-infected; prevention of mother-to-child transmission (PMTCT) programme
- Well, past five years and occasional current IDU (heroin x 1/week), alcohol twice weekly
- Recent weight loss 8 kg
- Examination: weight 56 kg, no fever, no peripheral signs of chronic liver disease, liver edge palpable

**Mr NS – 2**
- HIV antibody test positive
- WCC 1000 cells/mm³
- Hb 11 g/dl
- Platelets 43000/µl
- ALT 50 IU/ml
- What further investigations, advice, treatment should be considered?

**Mr NS – 3**
- WHO stage III
- HCVAb positive
- HBsAg negative; HBcAb positive
- Likely HCV infection, no evidence of HBV
- Management?

**Mr NS – 4**
- Cease alcohol
- Consider treatment for heroin addiction (e.g. methadone)
- Safe injection advice/education
- ART
  - AZT/3TC/EFV

**Mr NS – 5**
- Advice about symptoms of hepatotoxicity
  - Nausea and vomiting
  - Dark urine and jaundice
- At one-month follow up:
  - Feels well
  - Gains 5 kg, non-tender liver
  - Repeat Hb 11.4 g/dl; platelets 170 000 µl; WCC 2000 cells/mm³
  - ALT 160 IU/ml
- Management/advice?

---

*Annex 1*
Mr NS – 6

- Continue and monitor
- Initial hepatotoxicity commonly transient
- Future access to HCV treatment to be reconsidered

Hepatitis C: dos and don’ts

DO:
- Vaccinate against hepatitis B and A, if required
- Regular health check-ups
- Stop or reduce alcohol intake
- Protect from re-infection; having hepatitis C antibodies will not protect from re-infection
- Eat a balanced diet of fresh vegetables, fruits, beans, whole grains and lean meats; a healthy balance of protein in the diet
- Drink lots of fluids
- Exercise regularly
- Make a stress reduction plan

AVOID:
- Drinking alcohol
- Taking large amounts of acetaminophen (paracetamol)
- Acetaminophen and alcohol together can cause severe liver damage
- Breathing in pollutants, chemicals, cleaning products, fumes from paint, paint thinners, chemical solvents, spray adhesives, insect sprays and cleaners can be harmful to the liver
- Foods with high salt, sugar or fat content
- Fatty foods
- High doses of vitamins A, D, E or K
- Taking iron supplements unless advised by the doctor

Treatment of HIV in HCV co-infection – 1

- Abnormal LFT is common and often occur early and are asymptomatic so important to monitor symptoms and LFT
- Severe hepatotoxicity (symptoms +/or ALT > 5 x upper limit of normal [ULN]) USUALLY requires stopping ART
- Monitoring during initiation and treatment
  - HCV test and LFT prior to treatment
  - Question about symptoms, regular (every 3 months) + LFT during treatment
  - If NVP-containing ART, use with caution
    - Women have increased risk of reaction (rash without fever; fever and rash; fever, rash and hepatitis)

Management of hepatotoxicity in HCV/HIV coinfected individuals

- Overall rate 10%
  - Risk factors > 5 x ULN enzymes:
    - AST =/or ALT > 1.25 ULN at ARV commencement
    - Platelet count < 99 000/µl
    - Other hepatotoxic medications
    - Creatinine > 1.5 ULN
  - Mortality reduced in ART treated despite hepatotoxicity
  - Educate patient about symptoms of hepatotoxicity; jaundice; darkening of urine; right upper quadrant pain; nausea, anorexia, pruritus or fatigue
  - Mild initial abnormalities of LFT NOT indication to stop ART, rather to monitor

Treatment of HIV in HCV co-infection – 2

Choice of ART regimen

- Depends on individual, but avoid hepatotoxic drugs
- NNTRI-based regimens
  - Caution with NVP
- NTRI
  - Can cause hepatic steatosis (fatty liver)
  - AVOID ddI and d4T with RBV
- PI-based regimens
  - Can cause liver injury (especially high-dose RTV)

Hepatitis C terminology in treatment response

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Refers to</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVR</td>
<td>Early virological response</td>
<td>Usually a reduction in viral load 12 weeks into treatment, though this varies by level of reduction and timing</td>
</tr>
<tr>
<td>ETR</td>
<td>End-of-treatment response</td>
<td>Undetectable HCV RNA at the end of treatment</td>
</tr>
<tr>
<td>SVR</td>
<td>Sustained virological response</td>
<td>Undetectable HCV RNA at 24 weeks after completion of treatment. Obtaining a sustained virological response is often referred to as a “cure”</td>
</tr>
<tr>
<td>NR</td>
<td>Non-responder</td>
<td>No significant reduction in HCV RNA levels (&lt;2 log_10 after a specified interval of treatment (usually 24 weeks), or no significant decrease in HCV RNA, but never becomes HCV RNA undetectable during treatment. Some non-responders may have improved liver histology after treatment</td>
</tr>
</tbody>
</table>

Participant Manual
Management of coinfections in HIV-positive injecting drug users

Treatment of HCV in HIV coinfection

- Treatment is expensive which limits accessibility
- Current preferred treatment regimen:
  - Pegylated (PEG-IFN) interferon (SC weekly injection) + RBV 800 mg (PO daily) for 48 weeks (RBV weight-based in genotype 1)
- Effectiveness (SVR)
  - Sustained viral clearance in 27% interferon and 40% PEG/RBV overall, and up to 73% in genotype non-1 PEG/RBV
- Which virus to treat first currently uncertain – guidelines say:
  - Treat HIV first if CD4 <200 cells/mm³
  - Treat HCV first if CD4 >350 cells/mm³, significantly improved outcome if ART and plasma HIV RNA suppressed (consider concurrent ART)
- New treatments on the horizon, HCV protease inhibitors

HCV treatment - APRICOT study

Sustained virological response

<table>
<thead>
<tr>
<th>Treatment</th>
<th>% of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN alfa-2a + RBV</td>
<td>12%</td>
</tr>
<tr>
<td>PegIFN alfa-2a + Placebo</td>
<td>20%</td>
</tr>
<tr>
<td>PegIFN alfa-2a + RBV</td>
<td>40%</td>
</tr>
</tbody>
</table>


Treatment of HCV in HIV coinfection – 1

- Reinfection (infection with new virus)
  - Limited data, probably uncommon
  - Prevent with HCV transmission prevention interventions (needle–syringe programmes, etc.)
- Relapse (return of original virus)
  - Almost always happens in first six months after treatment
  - 10% in genotype 1
  - 2% in genotypes 2 and 3

Treatment of HCV in HIV coinfection – 2

- Treatment is difficult but effective to clear/cure HCV especially in favourable genotypes.
- Side-effects:
  - IFN:
    - Depression (treat aggressively with selective serotonin reuptake inhibitors [SSRI])
    - Flu-like symptoms (treat with paracetamol)
    - Neutropenia (reduce dose if <0.75, <0.5 may require cessation of treatment)
  - RBV
    - Haemolytic anaemia (may require dose reduction if symptomatic)
    - DO NOT use with ddI plus/minus d4T in liver failure

Treatment of HCV in HIV coinfection – 3

- Substance use treatment
  - Needs to be evidence-based (e.g. OST)
- Prevention of pregnancy
  - Treatment of HCV is teratogenic (for both males and females) therefore two forms of contraception should be used (barrier and oral contraceptive pill)
  - No pregnancy should occur before ~6 months of stopping RBV

Conclusion

- HCV/HIV coinfection is very common in HIV-infected IDUs
- Test for HCV plus LFT prior to HIV treatment if possible
- Treat HIV in all as indicated (WHO 3 or 4)
- Avoid alcohol, treat substance use
- Advise use of sterile injecting equipment
- Use NVP in HIV treatment with care
- Asymptomatic change in LFT not an indication to cease ARVs
- Monitor LFT during HIV treatment
- If possible consider HCV treatment, currently PEG/RBV, future HCV protease inhibitors

Annex 1
Hepatitis B coinfection

Management of hepatitis B in HIV-coinfected IDUs

**Epidemiology**

- 400 million infected worldwide, with 500,000 deaths each year as a result
- Endemic in Asia and Africa (10–15% chronically infected)
- Low prevalence in western Europe, North America and Australia
- Transmission
  - Mother-to-child (5% chance)
  - Close contact between infants, mother (perinatal)
  - Unprotected sex
  - Blood-to-blood (sharing injecting equipment, unscreened transfusions)
- Chronic infection very common in infancy, very uncommon in adult acute infection
- Epidemiology of HBV/HIV less well understood, though IDUs in Asia are at high risk

**Geographical distribution of chronic HBV infection**

![Map showing distribution of chronic HBV infection](image)


**Hepatitis B prevalence**

- Overall U.S. prevalence: 0.3%
- Asian Americans: ~10–13%

![Bar chart showing hepatitis B prevalence by ethnicity](image)

**Background: Hepatitis B virus**

- DNA hepadnavirus
- Infects liver cells (hepatocytes)
- Liver damage is from immune injury
- Eight hepatitis B genotypes: may relate to hepatocellular carcinoma (HCC)
  - A is pandemic (USA, Africa, W. Europe)
  - B and C are found in Asia
  - D in Southern Europe, India and Africa
  - E in West Africa
  - F in the USA, Central and South America
  - G in the USA and France
  - H unclear

**Background: HBV markers**

<table>
<thead>
<tr>
<th>Marker</th>
<th>Full form</th>
<th>Indicates</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg</td>
<td>Hepatitis B surface antigen</td>
<td>Current infection with hepatitis B (a carrier)</td>
</tr>
<tr>
<td>HBsAb</td>
<td>Hepatitis B surface antibody</td>
<td>Immunoprotection against hepatitis from either vaccination or previous exposure</td>
</tr>
<tr>
<td>HBeAg</td>
<td>Hepatitis B e antigen</td>
<td>Marker of active replication/active disease</td>
</tr>
<tr>
<td>HBeAb</td>
<td>Hepatitis B e antibody</td>
<td>Marker of inactive disease, so called &quot;e seroconversion&quot;</td>
</tr>
<tr>
<td>HBV DNA</td>
<td>Hepatitis B DNA</td>
<td>Presence indicates active replication and disease. Amount of DNA is &quot;HBV viral load&quot;</td>
</tr>
</tbody>
</table>
Management of coinfections in HIV-positive injecting drug users

Effect of HBV on HIV progression

- Early studies suggested HBV may increase HIV progression BUT following ART now considered that HBV infection does not accelerate HIV progression
- Acute post-ART flare 10–15% with reported mortality; risk CD4 count <200 cells/mm³
- Viral resistance is increased in HBV/HIV coinfected individuals, possible contributing factors:
  - Higher HBV viral load difficulty suppressing
  - Monotherapy
  - Interrupted treatment due to hepatotoxicity

Mr LM – 1

- 32-year-old male IDU
- Injects heroin/methamphetamine, often mixing these with diazepam, less drug use recently
- Began injecting at 19 years, spent four years in prison
- Diagnosed HIV-positive seven years ago, during prison sentence
- Abnormal liver function test: ALT 60 IU/ml
- Now shingles, oral candidiasis
- Management?

Adverse outcomes in chronic HBV: annual incidence

<table>
<thead>
<tr>
<th>Test combination</th>
<th>Results</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg, HBcAb, HbsAb</td>
<td>-,-,-</td>
<td>Susceptible to hepatitis B</td>
</tr>
<tr>
<td>HBsAg, HBcAb, HbsAb</td>
<td>-,+,-</td>
<td>Past history of HBV infection</td>
</tr>
<tr>
<td>HBsAg, HBcAb, HbsAb</td>
<td>-,-,+</td>
<td>Immune due to hepatitis B vaccination</td>
</tr>
<tr>
<td>HBsAg, HBcAb, HbsAb</td>
<td>-,-,-</td>
<td>Past history of HBV infection</td>
</tr>
</tbody>
</table>

Hepatitis B disease progression

- Effect of HBV on HIV progression
  - Higher HBV viral load
  - Reduced HBeAg seroconversion
  - Increased liver fibrosis and cirrhosis
  - No change in liver cancer rates
  - Increased liver-related mortality
  - Effective ART can reduce progression, but care needs to be taken
    - Resistance
    - Immune flares: early
    - Withdrawal hepatitis when cessation of 3TC and/or TDF
    - Drug toxicity with NVP (early) and RTV

Background: HBV markers

<table>
<thead>
<tr>
<th>Test combination</th>
<th>Results</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBsAg, HBcAb, HbsAb</td>
<td>-,-,-</td>
<td>Susceptible to hepatitis B</td>
</tr>
<tr>
<td>HBsAg, HBcAb, HbsAb</td>
<td>-,+,-</td>
<td>Past history of HBV with current immunoprotection</td>
</tr>
<tr>
<td>HBsAg, HBcAb, HbsAb</td>
<td>-,-,+</td>
<td>Immune due to hepatitis B vaccination</td>
</tr>
<tr>
<td>HBsAg, HBcAb, HbsAb</td>
<td>-,-,-</td>
<td>Past history of HBV infection</td>
</tr>
</tbody>
</table>

Effect of HBV on HIV progression

- Early studies suggested HBV may increase HIV progression BUT following ART now considered that HBV infection does not accelerate HIV progression
- Acute post-ART flare 10–15% with reported mortality; risk CD4 count <200 cells/mm³
- Viral resistance is increased in HBV/HIV coinfected individuals, possible contributing factors:
  - Higher HBV viral load difficulty suppressing
  - Monotherapy
  - Interrupted treatment due to hepatotoxicity

Mr LM – 1

- 32-year-old male IDU
- Injects heroin/methamphetamine, often mixing these with diazepam, less drug use recently
- Began injecting at 19 years, spent four years in prison
- Diagnosed HIV-positive seven years ago, during prison sentence
- Abnormal liver function test: ALT 60 IU/ml
- Now shingles, oral candidiasis
- Management?
Treatment of HIV in HBV coinfection

- Hepatotoxicity
  - Does occur and causes are similar to HCV/HIV coinfection
  - Immune
  - Hepatotoxicity
- Choice of ART regimen
  - Use ARVs with activity against hepatitis B (3TC, TDF) possibly better if combined improved efficacy and resistance (no RCT data yet)
- Monitoring during initiation and treatment
  - Test for hepatitis B (at least HBsAg) and do LFT prior to ART commencement
  - Monitor ALT regularly (every three months in the first year) during HIV treatment

Prevention of HBV in HIV infection

- Prevention
  - Safe sex (barrier protection)
  - Sterile injecting equipment
  - Vaccination of all IDUs (if no existing immunoprotection)
    - 0, 1 and 6 months or 0, 1, 2 and 12 months
    - Double dose (40 µg/dose); repeat post-ART if no response
    - Need CD4 count>200 cells/mm³ for immune response – CONSIDER delay until immune recovery

Currently available treatment of HBV

- **3TC 300 mg/day**
  - Cheapest, most prone to resistance (usually in 1–4 years), also used in HIV treatment
  - Reduces viral load in 85% of people
  - Few side-effects
- **TDF 300 mg/day**
  - Low resistance, also used in HIV treatment
  - Effective in 3TC-resistant hepatitis B
  - Well tolerated, may cause renal dysfunction (rare)
- **Emtricitabine (FTC) 200 mg/day**
  - Cross-resistance with 3TC
  - Reduces HBV viral load equivalent to 3TC
  - Side-effects include rash, skin pigmentation

Currently available treatment of HBV

- **Adefovir diviopoxil 10 mg/day**
  - Reduction HBV DNA substantial but slow
  - Not effective in HIV treatment at this dose
  - Renal toxicity at increased doses
  - Resistance develops slowly but not cross-resistant 3TC, reduced in combination with 3TC
- **Entecavir 0.5 mg/day or 1 mg/day in 3TC resistance**
  - Low rates of resistance, no effect HIV
  - Potent HBV suppression
  - PEG-IFN
    - Very expensive
    - Most effective treatment (weekly SC injections for 48 weeks)
    - Low resistance? But many side-effects especially in cirrhotics
    - No advantage in combination with 3TC

Participants Manual
Treatment of HBV in HIV coinfection

- In individuals requiring HIV treatment and HBV treatment:
  - ARTs with hepatitis B activity should be included in the regimen.
  - If only one agent available use 3TC: 3TC can be used alone but resistance will develop.
  - If other single agents, use TDF (better resistance profile).
  - If two agents possible, then 3TC plus TDF.
- In individuals requiring HIV treatment and not HBV treatment:
  - Type of ART regimen should be determined by normal indications.
  - If hepatitis B replication is under control (HBV DNA <4 log10 copies/ml), ART does not have to contain agents with dual activity.
- In individuals with cirrhosis:
  - These patients are at risk of hepatic decompensation (failure) when ART is initiated, particularly if CD4 count is low and HBV viral load is high.
  - Therefore use combination (e.g. 3TC + TDF) initially to reduce HBV viral load before commencement of full ART if possible.

Treatment of HBV in HIV coinfection: effectiveness

- HBV DNA level
  - This is called viral load and is the best way to monitor effectiveness of treatment. It is also the most expensive.
  - 3TC reduces viral load by almost 3–5 log10 copies/ml after one year of treatment.
  - ADV reduces viral load by 4 log10 copies/ml after one year of treatment.
  - TDF reduces viral load by 5 log10 copies/ml regardless of resistance to 3TC.
- HBVAg seroconversion
  - Development of HBeAb is a result of treatment which indicates control of replication.
  - Only a minority of individuals on treatment will obtain HBeAg seroconversion: 3TC 25%; ADV 30%; PEG-INF 30%.
- ALT levels
  - Cheapest, but can be difficult to interpret
  - Decreased viral load = decreased ALT
  - Decreased ALT levels = better histology (on liver biopsy) during therapy
  - ALT can rise during:
    - Control of viral replication (due to restoration of immune function)
    - Liver toxicity from drug therapy
    - Immune flares

Development of resistance to 3TC

Incidence of YMDD resistance increases with the duration of therapy


HBV treatment: resistance

- Most common with 3TC – 70% by four years
- Least common with TDF – rare single reports
- Dual therapy (ADV + 3TC) results in less risk of mutations–little data as yet
- Resistance mutations can be identified by analysis of HBV DNA, but this is expensive, recurrent HBV DNA, flare of ALT also occurs in some

Coinfection: HIV and HBV

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Year</td>
<td>Year 1</td>
</tr>
<tr>
<td>Incidence of YMDD resistance increases with the duration of therapy</td>
<td>20%</td>
</tr>
<tr>
<td>HBV polymerase resistance mutations</td>
<td>LAM</td>
</tr>
</tbody>
</table>
Feasibility of HBV treatment in resource-limited settings

- Can be difficult to treat HBV in HIV coinfection in resource-limited areas, therefore:
  - Vaccinate for HBV
  - Stabilize drug use (e.g. OST)
  - Advise reduction or cessation of alcohol use
  - Delay HBV treatment until commencement of ART unless cirrhotic and low CD4 count
  - Use ARVs with HBV suppression activity in the treatment of HIV
  - DO NOT withdraw 3TC without consideration of HBV disease (risk of flares)

Conclusion

- HBV is very common in HIV-infected IDUs.
- All HIV-positive IDUs should be screened for HBV.
- HIV-positive IDUs should be vaccinated against HBV if not immune.
- Treatment for HBV should be withheld until indication to treat HIV.
- HIV treatment regimens in the context of HBV should include those ARVs that suppress HBV.
- ALT should be monitored during HIV/HBV treatment.
- Combined 3TC/TDF should be considered in HIV/HBV coinfection and in 3TC resistance.
Presentation 9.2: Management of HIV/TB coinfection in IDUs

Session objectives
- Describe the epidemiology of HIV/TB coinfection in South-East Asia
- Use the WHO guidelines to prescribe co-trimoxazole (CTX) preventive treatment
- Describe care and treatment for HIV-infected IDUs with active TB
- Prescribe appropriate ARVs for HIV-infected IDUs with active TB

Management of HIV/TB coinfection in IDUs

Tuberculosis: pathogenesis

TB transmission
- Transmitted by inhalation of infectious droplet nuclei from infected person
- Sputum smear positive (SS+) pulmonary TB cases account for most TB transmission in the community
- Most TB infections (90% in non-HIV infected people) remain latent
- PLWHA and IDUs have higher rates of progression to active TB or reactivation of latent infection

Incidence of active TB in persons with positive tuberculin skin test

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>TB cases/1000 person-years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latent TB infection (&gt;1 year)</td>
<td>1.6</td>
</tr>
<tr>
<td>IDU HIV-negative</td>
<td>10</td>
</tr>
<tr>
<td>Recent TB infection (&lt;1 year)</td>
<td>12.9</td>
</tr>
<tr>
<td>IDU HIV-positive</td>
<td>76</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>35–162</td>
</tr>
</tbody>
</table>


TB/HIV coinfection
- TB is the most common opportunistic infection (OI) among HIV-infected patients in developing countries
- IDUs have a higher incidence of active TB infection, regardless of HIV status
- The manifestations of TB may be different in PLWHA
- WHO recommends screening:
  - ALL TB patients for HIV (voluntary counselling and testing (VCT))
  - ALL HIV patients for TB infection


Management of coinfections in HIV-positive injecting drug users

Prevalence of OIs among persons with AIDS, Thailand (2 series)

- Tuberculosis: 29–37%
- Cryptococcosis: 19–38%
- Wasting syndrome: 8–28%
- P. jiroveci pneumonia (PCP): 5–20%
- Bacterial pneumonia: 4%
- Oesophageal candidiasis: 3–6%
- Penicillium marneffei infection: 3%
- Toxoplasmosis: 2–3%
- Cryptosporidiosis: 1–2%


Causes of respiratory infections among 295 PLWHAs in Cambodia

- TB: 39%
- PCP: 30%
- Bacteria: 16%
- Mycosis: 6%
- Non-TB mycobacteria: 5%
- Strongyloides: 4.7%
- Cancer: 0.3%


Pneumocystis jiroveci pneumonia (PCP)

- Common cause of respiratory infections in SE Asia
- Increased risk with CD4 count <200 cells/mm³
- Prevention: CTX 960 mg once a day
- WHO criteria for CTX prophylaxis in adults:
  - No CD4 testing: WHO clinical stages 2, 3, 4
  - CD4 testing available:
    - WHO clinical stages 3-4
    - CD4 count <200 cells/mm³ (for PCP and toxoplasmosis)

CTX prevents many infections in PLHWA:

<table>
<thead>
<tr>
<th>Infection</th>
<th>Pathogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>Pneumocystis jiroveci</td>
</tr>
<tr>
<td></td>
<td>Strep. pneumoniae</td>
</tr>
<tr>
<td>Bacteriaemias</td>
<td>Salmonella</td>
</tr>
<tr>
<td></td>
<td>Strep. pneumoniae</td>
</tr>
<tr>
<td>Encephalitis</td>
<td>Toxoplasma gondii</td>
</tr>
<tr>
<td>Skin infections</td>
<td>Staph. and Strep. species</td>
</tr>
<tr>
<td>Protozoa</td>
<td>Malaria</td>
</tr>
</tbody>
</table>

2006 WHO guidelines for CTX prophylaxis in infants and children

- CTX prophylaxis is universally indicated, starting at four to six weeks after birth and maintained until cessation of risk of HIV infection.
- CTX prophylaxis is indicated regardless of CD4 percentage or clinical status.
- Universal option prophylaxis for all infants and children born to mothers confirmed or suspected of living with HIV. This strategy may be considered in settings with high prevalence of HIV high infant mortality due to infectious diseases and limited health infrastructure (CIV)

CTX distribution in 100 HIV/AIDS patients at Tropical Disease Hospital (HCMC, Viet Nam) – 2000

- Oral thrush: 53%
- Tuberculosis: 37%
- Wasting syndrome: 34%
- Respiratory infections: 13%
- Cryptococcosis: 9%
- Penicilliosis: 7%
- PCP: 5%
- Septicaemia: 4%

Management of coinfections in HIV-positive injecting drug users

Treatment of active TB infection

General principles:
- Treatment of TB in PLWHA is the same as in non-HIV-infected patients
- Follow national guidelines for TB treatment
- Usual regimens for pulmonary and extrapulmonary TB:
  - Two months intensive phase: RH52 or RH5Z
  - Consolidation phase: four months RH or six months HE
- Treatment for TB meningitis (9–12 months)

Treatment of latent TB infection

- Latent TB infection is diagnosed by tuberculin skin testing (TST)
- Rule out active TB infection before treating latent infection to avoid drug resistance
- Prophylaxis has been shown to decrease active TB infection for up to three years
- Refer to national TB programme guidelines
- Cautions: monitor for signs of hepatotoxicity
- Add pyridoxine 25–50 mg/day to INH to prevent neuropathy
- Be aware of interactions and cross-toxicities between ARV and TB drugs

ART and TB

- HIV-infected persons with active TB will often be offered ART because those with pulmonary TB meet criteria for WHO stage 3 and those with extrapulmonary TB for WHO stage 4
- ART may be highly beneficial in these persons in reducing case-fatality rates in TB
- Patients already receiving ART may develop clinical TB
- TB treatment should be initiated promptly regardless of the HIV serostatus

PCP prophylaxis

- For patients allergic to CTX:
  - Dapsone: adults 100 mg once a day
- When can CTX be stopped?
  - Adults:
    - CD4 count >200–350 cells/mm³ after six months of ART
    - If no CD4 count available: on ART for one year with no new clinical stage 2, 3, or 4 events

CTX preventive treatment (CPT) significantly decreases mortality and hospital admissions in HIV-associated active TB

![Graph showing the comparison between deaths and hospital admissions with and without CPT.](image)


Annex 2
Management of coinfections in HIV-positive injecting drug users

Co-management of HIV and TB is challenging
- Drug interactions between rifampicin and several classes of ARVs
- High pill burden
- Adherence problems
- Drug toxicity
- Immune reconstitution inflammatory syndrome (IRIS)

TB and ARV: general principles
- Treat TB first! The patient should be tolerating TB therapy for at least two weeks before starting a new ART regimen.
- Do not stop the ART! – if the patient is already on ART before the diagnosis of TB
  - Be aware of the interactions between TB therapy and ARV drugs
  - Change the ART regimen if needed and available (i.e. change NVP to EFV)
- Start ART! Consider starting ART as soon as possible following WHO and national guidelines.

When to start ART in adults and adolescents with active TB disease
- Optimal timing of initiation of ART is not known.
- Case-fatality rates in patients with TB during the first two months of TB treatment are high.
- Where CD4 counts are not available, WHO recommends that ART be considered in all patients after the intensive phase of TB treatment.

When to start ART in adults and adolescents with active TB disease: WHO 2006

<table>
<thead>
<tr>
<th>CD4 count cells/mm³</th>
<th>ART recommendations</th>
<th>ART timing after TB treatment started</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;200</td>
<td>Recommend ART</td>
<td>2–8 weeks</td>
</tr>
<tr>
<td>200–350</td>
<td>Recommend ART</td>
<td>After 8 weeks</td>
</tr>
<tr>
<td>&gt;350</td>
<td>Defer ART (1)</td>
<td>Re-evaluate at 8 weeks and after TB treatment completed</td>
</tr>
<tr>
<td>not available</td>
<td>Recommend ART (2)</td>
<td>2–8 weeks</td>
</tr>
</tbody>
</table>

Notes: (1) Consider ART if other non-TB stage 3-4 conditions are present.
(2) If clinically stable and responding to TB treatment, can defer ART until after TB treatment completed.

What ART to start? WHO 2006 recommendations

- Preferred regimen: 2 NRTI + EFV
  - Do not use in the first trimester of pregnancy
- Alternate regimen: 2 NRTI + NVP
  - ↓ NVP levels with rifampicin
  - Do not use in women with CD4 count >250 cells/mm³
  - Monitor carefully for hepatotoxicity (ALT at 4, 8, 12 weeks)
- Triple NRTI option: AZT + 3TC + (ABC or TDF)
  - Safe for pregnant women, women with CD4 count >250 cells/mm³, hepatitis
  - Concern about lower efficacy than NNRTI-containing regimens

First-line ART regimens in the setting of TB treatment for adults and adolescents

### Active TB in adults and adolescents already on ART

**Issues:**
- Does a new diagnosis of TB in a patient on ART represent treatment failure?
- Do first-line regimens need to be changed?
- Do second-line regimens need to be changed?

### Do first-line regimens need to be changed?

- EFV-based or triple-NRTI regimens can be continued.
- Options for NVP-based regimens:
  1. Switch to EFV-based or triple-NRTI regimen
     - Can switch back to NVP when rifampicin therapy completed
  2. Continue NVP-based regimen
     - Monitor closely for hepatotoxicity

### Active TB in adults and adolescents already on ART

**Do second-line regimens need to be changed?**

- Unboosted PI cannot be taken with rifampicin due to decreased levels of the PI
- Options for second line:
  - 2 NRTI + LPV/RTV
  - 2 NRTI + SQV/RTV
  - RTV + rifampicin have ↑ risk for hepatic toxicity: monitor clinical signs and ALT closely

### Immune reconstitution inflammatory syndrome (IRIS)

- Paradoxical development of new signs and symptoms of OI, or worsening of symptoms of a previously treated OI after initiation of ART
- Usually occurs in the first 2–12 weeks of ART
- Occurs in up to 33% of TB patients who start ART
- Increased risk for IRIS if ART started soon after TB treatment or with low CD4 counts
- Symptoms of TB-IRIS include fever, lymphadenopathy, and worsening of respiratory disease

### IRIS: treatment

- Rule out new or recurrent OI
- Continue ART unless symptoms are very severe or life-threatening
- IRIS will resolve in several weeks without specific treatment
- Treat symptoms as appropriate (e.g., NSAIDs or paracetamol for fever and pain)
- Severe symptoms can be treated with steroids
  - Prednisone 0.5–1.0 mg/kg/day for 1–2 weeks then taper
**Conclusions**

- TB and HIV are often found together: screen all IDU patients for both
- Recommend CTX prophylaxis to all HIV-positive TB patients
- Same TB treatment for HIV-infected and uninfected patients: follow national guidelines
- ART should be considered in all patients with TB/HIV coinfection
- Be aware of the interactions and overlapping toxicities of TB drugs and ART
- IRIS is common in TB patients after starting ART

**TB associated IRIS**

TB patient with worsening lymph node enlargement and drainage after starting ART

**TB IRIS**

27-year-old male IDU in northern Viet Nam at month 5 of treatment for pulmonary TB. Presents after six weeks of ART with increased cough, fatigue and fever. Sputum AFB X 3 negative. Symptoms resolved after four weeks' treatment with diclofenac.

**Case study 1**

A 36-year-old male presents with a four-week history of fever, cough, fatigue, poor appetite and a six kg weight loss. He just tested positive for HIV in the VCT today and was referred to the clinic for further evaluation. He does not have any previous illnesses and is not on any medications.

He first injected drugs in 1999 and quit in 2003. He currently works as a motorcycle taxi driver and lives with his wife.

**Case study 1 (cont.)**

Physical exam:
- Temp 39, HR 110, BP 110/90, RR 18, weight 44 kg
- HEENT: oral thrush
- Neck: multiple lymph nodes on the right side 1–2 cm
- Lungs: scattered rales, no wheezing
- Heart, abdomen: normal
- Skin: no rashes

**Case study 1: right supraclavicular lymphadenopathy**

Source: D Colby
Case study 1 (cont.)

Questions:
1) What WHO clinical stage is the patient in?
2) What further evaluation is required?

Case study 1: CXR

Source: D Colby

Case study 1 (cont.)

Results of laboratory testing:
- CBC: WBC 3600 (25% lymphocytes)
- Haematocrit 31%, Hb 9.2, platelet 135 000
- CD4: 95 cells/mm³
- ALT 46 IU/ml, AST 50 IU/ml
- HCV positive, HBsAg negative
- AFB x 3 negative

Case study 1 (cont.)

Questions:
3) What is the most probable diagnosis?
4) What further diagnostic evaluation would you do?

Case study 1: treatment

7) What do you treat first: the TB or the HIV?
   - Start TB treatment first and consider ART when indicated
8) Does the patient fulfil criteria for starting ART?
   - Yes, WHO stage 4 and CD4 count 95 cells/mm³
9) When will you start ART?
   - Between 2 and 8 weeks, as soon as the patient is tolerating TB treatment
10) What ART would you start?
    - Preferred regimen: 2 NRTI + EFV
     - Other options: 2 NRTI + NVP, 3 NRTI

Result: aspiration of a cervical lymph node is positive for AFB
5) What is the diagnosis?
6) What is the WHO clinical stage of the patient?
Case study 2
A 20-year-old male patient returns to the clinic for routine follow up. He started ART with d4T/3TC/NVP six weeks ago. Baseline CD4 count was 105 cells/mm³. At four weeks he was feeling well without symptoms and results of routine blood testing (CBC, ALT, AST) were normal. Today he complains of fever, cough with white sputum, and a 1 kg weight loss over the past 10 days.

His medical history is notable for chronic HBV infection and one episode of herpes zoster two years ago. He smokes ½ pack of cigarettes a day. No alcohol. He still uses heroin twice a day, but has been trying to decrease the amount he uses each time.

1) Does the patient fulfill criteria for starting ART?
   - Yes, clinical stage 3 (pulmonary TB) and CD4 count <350 cells/mm³

2) Does current injecting drug use disqualify the patient for ART?
   - No, active drug use is not a reason to deny care or ART.
   - However, the patient should be referred for counselling and drug treatment, where available.
   - Drug use can be associated with decreased adherence: active IDUs should be carefully counselled and monitored for adherence.

3) When would you start ARV on this patient?
   - After 8 weeks, when the intensive phase of TB treatment is completed

4) What ARV regimen would you use?
   - If the patient continues on rifampicin:
     - EFV-based regimens preferred
   - If the patient continues on HE:
     - EFV or NVP regimens can be given
   - NOTE: The patient has high risk for hepatic toxicity due to chronic HBV and HCV infection, baseline elevated ALT, and use of TB drugs. Check ALT at eight weeks before starting ART and follow closely.

Case study 2 (cont.)
Physical examination: no significant abnormalities
Laboratory examination:
- CBC: WBC 5600 (25% lymph), Hb 10, platelet 155 000
- CD4 225 cells/mm³
- ALT 76 IU/ml, AST 65 IU/ml
- HCV positive, HBsAg positive

Case study 3
A 24-year-old male patient is referred from the TB clinic after testing positive for HIV. He is in the third week of treatment for pulmonary TB and is tolerating the treatment well. His fever has resolved and he has gained 2 kg since starting treatment. His cough is better but he still coughs at night.

His medical history is notable for chronic HBV infection and one episode of herpes zoster two years ago. He smokes ½ pack of cigarettes a day. No alcohol. He still uses heroin twice a day, but has been trying to decrease the amount he uses each time.

Physical exam:
- Temp 38.0, RR 16, HR 88, BP 120/76
- HEENT: no thrush
- Neck: no lymphadenopathy
- Lungs: rales and wheezing on the upper left side
- Heart: regular rhythm without murmurs
- Abdomen: normal
- Skin: no rashes
3) The patient is started on RHZE for TB. Will you stop the ART?
- NO! DO NOT STOP THE ART! You should continue ART while treating the TB.

4) Will you change the ART regimen?
- Concerns about NVP use with rifampicin
- Preferred regimen is 2 NRTI + EFV, if available
- Other options: 3 NRTI or continue 2 NRTI + NVP
- If NVP continued: monitor closely for hepatic toxicity

1) What is the diagnosis?
- Active pulmonary TB

2) Is this failure of the ART regimen?
- No, development of active pulmonary TB while on ART does not indicate treatment failure and is common in the first six months of treatment
**Module 9**

**Management of Coinfections in HIV-Positive Injecting Drug Users**

Treatment and Care for HIV-Positive Injecting Drug Users